

Kiniksa Pharmaceuticals International, plc

Annual report and financial statements

31 December 2025

Kiniksa Pharmaceuticals International, plc

Company Information	3
Strategic Report	4
Directors' Report	10
Directors' Remuneration Report	16
Independent auditors' report to the members of Kiniksa Pharmaceuticals International, PLC Report on the audit of the group financial statements	61
Certain Note Disclosures Relevant to the Group Financial Statements	84

Kiniksa Pharmaceuticals International, plc

Company Information

Current Directors
(each, a “**Director**”)

S. K. Patel
F. J. Baker
S. R. Biggar
M. C. Boyd
G. B. Cole
R. S. Levy
T. R. Malley
T. L. McCain
K. J. Popovits
B. D. Quart

Company secretary

D. J. Barry
(appointed on 18 September 2025)

M. D. Zeylikman
(resigned 18 September 2025)

Registered number

15630565

Registered office

Second Floor
105 Piccadilly
London
W1J 7NJ

Independent auditor

PricewaterhouseCoopers LLP
One Station Hill
Garrard Street
Reading
RG1 1NR

Solicitors

Ropes & Gray International LLP
60 Ludgate Hill
London
EC4M 7AW

Kiniksa Pharmaceuticals International, plc
Strategic report
For the year ended 31 December 2025

Strategic Report

Introduction

The Directors present the Directors' strategic report of Kiniksa Pharmaceuticals International, plc ("**Kiniksa International**") for the year ended 31 December 2025. References to "Kiniksa International" in this annual report shall mean Kiniksa Pharmaceuticals International, plc only.

Kiniksa International is a public limited company that was incorporated in England and Wales in April 2024, with company number 15630565. The Company's UK headquarters and registered office address is 105 Piccadilly, Second Floor, London, England, W1J 7NJ. Kiniksa International is a holding company for the Group (as defined below), which conducts its business entirely through Kiniksa International's direct and indirect subsidiaries, with principal places of operations in the United States, United Kingdom and Switzerland. The Group's US headquarters are located at 100 Hayden Avenue, Lexington, MA 02421.

Kiniksa International is a holding company for the Group, which together comprises a biopharmaceutical company that develops and commercializes novel therapies for diseases with unmet need, with a focus on cardiovascular indications.

Kiniksa International, incorporated on 9 April 2024, is the successor issuer to Kiniksa Pharmaceuticals, Ltd. ("**Kiniksa Bermuda**"). On 27 June 2024, Kiniksa International and Kiniksa Bermuda completed a transaction pursuant to a Bermuda court-approved scheme of arrangement (the "**Scheme**"), which had been previously approved by Kiniksa Bermuda's shareholders. Pursuant to the Scheme, the shareholders of Kiniksa Bermuda became the shareholders of Kiniksa International and Kiniksa International became the ultimate parent and holding company of the Kiniksa organization, thereby effecting a change of incorporation from Bermuda to the United Kingdom (the "**Redomiciliation**"). As used herein, and unless the context otherwise requires, references to "we", "us", "our", "Kiniksa", the "Company" or the "Group" in this report prior to the Redomiciliation shall refer to Kiniksa Bermuda (and its consolidated subsidiaries) and from and after the Redomiciliation, to Kiniksa International (and its consolidated subsidiaries). In November 2025, Kiniksa Bermuda was liquidated, completing the Redomiciliation.

Kiniksa International's Class A ordinary shares ("**Class A Shares**") are listed on the Nasdaq Global Select Market ("**Nasdaq**") under the trading symbol "KNSA" and Kiniksa International has filed an Annual Report on Form 10-K for the year ended 31 December 2025 (the "**Form 10-K**"), along with subsequent quarterly and current reports, with the U.S. Securities and Exchange Commission (the "**SEC**"), which contain certain additional disclosures regarding some of the matters discussed in this report.

The accounts comprise the financial statements for the Group for the 12 months ended 31 December 2025 and 2024.

Kiniksa Pharmaceuticals International, plc
Strategic report
For the year ended 31 December 2025

The functional currency of the Group is US dollars.

Required Item in the Strategic Report	Where Information Can Be Found in the Form 10-K
A fair review of the group's business	Part I – Item 1. Business Part I – Item 2. Properties Part II – Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations Kiniksa International's principal activity is that of a holding company and publicly-traded parent of the Group, whose primary business is the development and commercialization of novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Refer to "Notes to the Financial Statements" for more information regarding Kiniksa International's investments in its subsidiaries.
A description of the principal risks and uncertainties	Part I – Item 1A. Risk Factors Part II – Item 7A. Quantitative and Qualitative Disclosures About Market Risk
Analysis of the development and performance of the Company's business during the financial period	Part I – Item 1. Business Part II – Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations
Main trends and factors likely to affect the future development, performance and position of the Company's business	Part I – Item 1. Business Part I – Item 1A. Risk Factors Part II – Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations
Information about the Company's employees	Part I – Item 1. Business
Description of the Company's business model	Part I – Item 1. Business
Explanation of amounts included in the Company's annual accounts	Part II – Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations Consolidated Financial Statements, including the Notes Thereto

Other information required within the Strategic Report which is not included in the Form 10-K

Financial key performance indicators

The Directors use key performance indicators to monitor and assess our performance. In the year ended 31 December 2025, our key performance indicators were turnover, cash at bank and in hand and gross

Kiniksa Pharmaceuticals International, plc
Strategic report
For the year ended 31 December 2025

profit. For more information on each of these key performance indicators, please see the financial statements that follow this Strategic Report.

Key Performance Indicator (\$m)	Year Ended 31 December		Change (\$m)	Change (%)
	2024	2025		
<i>Turnover</i>	423	678	255	60.28 %
<i>Cash at bank and in hand</i>	184	166	(18)	(9.78)%
<i>Gross profit</i>	362	600	238	65.75 %

The Directors, assisted by the Company's senior management, consider each of these indicators when determining the Company's past performance and future operational plans and goals. With respect to turnover, it is a metric useful to determine the effectiveness of our commercial operations on a year-over-year and quarter-over-quarter basis. Cash at bank and in hand is a useful metric to determine our overall cash burn rate, which informs how much cash we can allocate amongst our operational, research, development and commercial expenses. Lastly, gross profit is helpful for determining our overall commercial performance against such expenses. In each case, we think these indicators are also useful for our investors in determining the growth and success of our organization.

Social, Community and Human Rights Issues

The Company does not, at present, have a specific policy on human rights. However, we maintain a number of policies intended to promote a compliant and ethical business. See Part I – Item 1. Business – Human Capital of the Form 10-K for more information on our commitment to ethics in the workplace and healthy and safe working conditions. In accordance with UK law, the Company performs an annual assessment of risks related to slavery and human trafficking in its business and supply chain. The results of such assessment are included in the Company's annual Modern Slavery Act Statement, which can be found on our corporate website at <https://www.kiniksa.com/compliance-ethics>.

Diversity and Equality

Hiring decisions within the Group are made on merit according to the balance of skills and experience offered by prospective candidates, compared to the needs of the Company. While acknowledging the value of a wide range of perspectives at all levels of our company, individual appointments are made irrespective of personal characteristics such as race, disability, gender, sexual orientation, religion or age.

A breakdown of employment statistics as of 31 December 2025 is as follows:

Position	Male	Female	Declined	
			to Answer	Total
<i>Executive Leadership Team (EVPs, SVPs and CEO)</i>	8	3	—	11
<i>VPs and GVPs</i>	9	4	3	16
<i>Managers</i>	36	37	3	76
<i>Other Employees</i>	107	149	6	262
Total Employees	160	193	12	365
<i>Non-Executive Directors</i>	6	3	—	9
Total Employees and Directors	166	196	12	374

Kiniksa Pharmaceuticals International, plc
Strategic report
For the year ended 31 December 2025

Directors' statement of compliance with duty to promote the success of the Company

The Directors have acted in a way that they have considered, in good faith, to be most likely to promote the success of Kiniksa for the benefit of our members as a whole, considering the factors listed in section 172 (1) of the Companies Act 2006.

Our success is the driving factor behind all the decisions we make, and our decision-making processes are structured to enable us to evaluate the merit of proposed business activities and the likely consequences of our decisions, as well as the interests of our stakeholders.

Our Stakeholders

Patients. Our patients are central to our business. The core of our strategy is the identification, development and commercialization of therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. We put patients first and live by our motto: Every Second Counts™.

Employees. We aim to cultivate a highly skilled and passionate team determined to deliver transformative therapies to the patients who need them most. We believe that the success and growth of our business depends in large part on our continued ability to attract, retain and motivate qualified personnel at all levels of our company. See Part I – Item 1. Business – Human Capital of the Form 10-K for more information on our commitment to employee welfare.

Shareholders. Our Class A Shares are listed on Nasdaq under the trading symbol “KNSA”. The execution of our business strategy, as described in Part I – Item 1. Business of the Form 10-K, directly impacts the value of our traded shares in conformance with our obligations to promote the success of the Company for the benefit of our shareholders as a whole. Further, we recognize the need to maintain good relationships with our shareholders. We understand the importance of effectively communicating our operational and financial performance as well as our future strategy, which we do through our investor website, periodic news releases and periodic reports filed with the SEC, including the Form 10-K. Shareholders are encouraged to contact the Company, via its investor relations team, with concerns and questions.

Government and Regulators. We conduct business with honesty and integrity and in compliance with applicable laws and regulations. Maintaining ethical and respectful relationships with government agencies, policy makers and other public officials is an important element of how we do business.

As part of our dedication to fulfilling government and industry regulatory requirements and expectations, our team operates under current good manufacturing practice, good clinical practices and good laboratory practices, each as prescribed by the U.S. Federal Food and Drug Administration (“FDA”) or similar foreign regulatory bodies. We employ a number of highly skilled subject matter experts in various compliance, legal, financial and regulatory departments to ensure ongoing compliance with other legal and regulatory requirements.

Community and Environment. We fully support our staff to give back to the communities in which we operate. We sponsor a number of charitable events intended to engage the communities in which we operate. Further, we have sponsored initiatives, such as the American Heart Association’s *Addressing Recurrent Pericarditis* initiative, to support disease awareness. Our dedication to local, national and international causes is mirrored by our mission to help patients and caregivers facing devastating unmet illnesses.

In addition, we are conscious of our environmental impact. Our Massachusetts-based facility, which produces drug substance to support research, preclinical and other clinical development for our product

Kiniksa Pharmaceuticals International, plc
Strategic report
For the year ended 31 December 2025

candidates, has oriented its operations to lessen its environmental impact, including using inert chemicals that minimize bioaccumulation in its drug manufacturing and testing processes. In addition, the facility engages industry-recognized providers who adhere to government-mandated guidelines when removing hazardous and biological waste. We are regularly investigating ways to improve the efficiency of our offices and operations and are conscious of their impact on pollution. As new methods become available and commercially reasonable, we expect to adopt them into our daily operations.

Our research, development, testing and manufacturing activities are subject to various climate, health and safety laws and regulations. We use our best efforts to ensure that we and the third parties with whom we contract, comply with such laws and regulations. Failure to comply could subject us to fines or other sanctions, potentially materially harming our ability to do business.

Principal Decision

A principal decision taken by the Board in the year ended 31 December 2025 was the initiation of our Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis. KPL-387 represents an exciting opportunity for our company and our patients by expanding the recurrent pericarditis market and providing an additional treatment option for patients, with the potential to add the convenience of monthly subcutaneous self-administration with a liquid formulation.

In addition, the Board reviewed and approved a long-term incentive plan to encourage KPL-387 development, as further discussed in “Summary of Policy – Executive Directors” in the Directors’ Remuneration Report below. The plan’s design was informed by diligent industry and peer analysis and intended to provide challenging, yet achievable, goals for our employees to strive for: the submission of a biologics license application with the FDA and the receipt of marketing approval for KPL-387 in recurrent pericarditis by the FDA. The Board will monitor progress towards these goals and expects to use such progress to inform further strategic decision-making.

Each of the above-described actions were done in compliance with the requirements of section 172 (1) of the Companies Act 2006. Execution on our strategic plans for KPL-387 is expected to generate significant value for the Company, its patients and its shareholders, each of which are key stakeholders outlined above.

Governance and Climate Risk Management

We regularly consider risks facing our business, including climate-related risks, in our strategic plans. Members of management contribute to these efforts, with no single role entirely responsible for overseeing all of our climate-related impact. We do not have formalized climate-related oversight but instead monitor and address associated risks as they arise and often rely on our third-party contractors to assist in such monitoring activities. Initial assessments of materiality are made by members of our management, with matters deemed material enough reported to our Nominating and Corporate Governance Committee, which monitors risks related to environmental, social and corporate governance matters. Our Board (as defined below) makes final determinations of materiality and advises on risk management and mitigation strategies. In the event that action is required, our team works to carry out risk management and mitigation. Progress on established goals is monitored by our personnel, who in turn report to senior management and our Board. Climate-related risks that may impact us include those described Part I – Item 1A. Risk Factors of the Form 10-K.

Kiniksa Pharmaceuticals International, plc
Strategic report
For the year ended 31 December 2025

As detailed below under “Greenhouse gas emissions, energy consumption and energy efficiency action”, our activities carry a minimal impact on the climate. However, as discussed under “Our Stakeholders – Community and Environment” we nonetheless take our obligations seriously, consider climate-related risks in our strategic outlook and look for ways that we and the third parties with whom we contract can minimize our impact. To support our focus on climate-related matters and sustainability, we may in the future engage in resiliency modeling, develop climate and sustainability-related targets and key performance indicators to assess progress against those targets, perform financial performance impact analysis, integrate climate-related issues into our financial planning and engage in climate risk categorization (including with respect to physical vs. transition and short vs. medium vs. long-term risks), though we have not done so at the time of this report.

We do not currently conduct scenario analyses, nor have we established any climate-related targets to manage climate-related risks or to realize climate-related opportunities (and, consequently do not track climate-related key performance indicators) because our Directors do not consider such matters to be necessary for an understanding of our business. Further, we have not identified any climate-related opportunities specific to our operations.

This report was approved by the Board and signed on its behalf.

DocuSigned by:

9EFBEB991C6E4E0...
Sanj K. Patel
Director
Date: 19 March 2026

Kiniksa Pharmaceuticals International, plc
Directors' report
For the year ended 31 December 2025

Directors' Report

The Directors present their report and the Company's audited consolidated financial statements for the year ended 31 December 2025. Where the requirements of the Directors' Report in accordance with the Companies Act 2006 have been met in the Form 10-K, details have been provided in the table below and reference made in the Form 10-K accordingly. Additional requirements which are not met by the Form 10-K have been disclosed separately at the end of the Directors' Report. The Form 10-K is attached at the end of this report and forms part of this report by cross reference.

Required Item in the Directors' Report	Where information can be Found in the Form 10-K
The financial risk management objectives and policies of the entity, including the policy for hedging each major type of forecasted transaction for which hedge accounting is used	Part I – Item 1A. Risk Factors Part II – Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations
Business Relationships	Part I – Item 1. Business
Credit risk	Part IV – Notes to Consolidated Financial Statements, Note 2
Liquidity risk and cash flow risk	Part I – Item 1A. Risk Factors Part IV – Notes to Consolidated Financial Statements, Note 1
Price risk	Part I – Item 1A. Risk Factors
An indication of the Group's activities in the field of research and development	Part I – Item 1. Business Part I – Item 1A. Risk Factors Part II – Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations
An indication of the Group's engagement with suppliers, customers and others	Part I – Item 1. Business Part I – Item 1A. Risk Factors Part II – Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations Part IV – Notes to Consolidated Financial Statements, Note 2
Branches outside the UK	Part IV – Notes to Consolidated Financial Statements, Note 1
Structure of the Group's capital	Consolidated Statements of Shareholder Equity
Statement on dividends	Part II – Item 5. Market For Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Going concern	Part IV – Notes to Consolidated Financial Statements, Note 1
Post-balance sheet events	Part IV – Notes to Consolidated Financial Statements, Note 19
Future Developments	Part I – Item 1. Business Part I – Item 1A. Risk Factors Part II – Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations
Information on contracts of significance	Part I – Item 1. Business Part IV – Item 15. Exhibits and Financial Statement Schedules

Kiniksa Pharmaceuticals International, plc
Directors' report
For the year ended 31 December 2025

Other information required within the Directors' Report which is not included in the Form 10-K

Directors

The Directors who served during the year and up to the date of signing of the consolidated financial statements were:

S. K. Patel
F. J. Baker
S. R. Biggar
M. C. Boyd
G. B. Cole
R. S. Levy
T. R. Malley
T. L. McCain
K. J. Popovits
B. D. Quart

Statement of Directors' Responsibilities in Respect of the Financial Statements

The Directors are responsible for preparing the Annual Report and the financial statements in accordance with applicable law and regulation.

Company law requires the Directors to prepare financial statements for each financial year. Under that law the Directors have prepared the Group's financial statements in accordance with accounting principles generally accepted in the United States of America ("**US GAAP**") and parent company financial statements in accordance with United Kingdom ("**UK**") Generally Accepted Accounting Practice (United Kingdom Accounting Standards, comprising FRS102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", and applicable law).

Under company law, the Directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Group and Company and of the profit or loss of the Group for that period. In preparing the financial statements, the Directors are required to:

- select suitable accounting policies and then apply them consistently;
- state whether applicable UK-adopted international accounting standards have been followed for the Group financial statements and United Kingdom Accounting Standards, comprising FRS 102 have been followed for the Company financial statements, subject to any material departures disclosed and explained in the financial statements;
- make judgements and accounting estimates that are reasonable and prudent; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Group and the Company will continue in business.

The Directors are responsible for safeguarding the assets of the Group and company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Kiniksa Pharmaceuticals International, plc
Directors' report
For the year ended 31 December 2025

The Directors are also responsible for keeping adequate accounting records that are sufficient to show and explain the Group's and the Company's transactions and disclose with reasonable accuracy at any time the financial position of the group and company and enable them to ensure that the financial statements and the Directors' Remuneration Report comply with the Companies Act 2006.

The directors are responsible for the maintenance and integrity of the company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Directors' Confirmations

In the case of each Director in office at the date the Directors' Report is approved:

- so far as the Director is aware, there is no relevant audit information of which the Group's and the Company's auditors are unaware; and
- they have taken all the steps that they ought to have taken as a Director in order to make themselves aware of any relevant audit information and to establish that the Group's and the Company's auditors are aware of that information.

Results and dividends

The Company recorded net income of \$80.8 million for the year ended 31 December 2025, after taxation.

During the year ending 31 December 2025, no dividends were paid by the Company. No interim or final dividends have been proposed by the Company.

Purchases of own shares during the year

The Company did not purchase or place a charge on its own shares in the year ending 31 December 2025.

Directors' Indemnities

The Company has entered into qualifying third-party indemnification agreements for the benefit of its Directors and which remain in force as at the date of approving the Directors' Report. The Company additionally maintained Director and officer liability insurance throughout the year ending 31 December 2025.

Political Contributions

The Company has not made any political donations or incurred any political expenditure during the period.

Employee Engagement

The Company is not required to report on employee engagement in the Directors' Report because it did not meet the threshold requirement of an average of more than 250 UK employees in the Group in two consecutive years. However, the Company is committed to its relationship with its employees as further described in the Section 172 (1) statement set out in our Strategic Report.

Kiniksa Pharmaceuticals International, plc
Directors' report
For the year ended 31 December 2025

Greenhouse gas emissions, energy consumption and energy efficiency action

Quantification and reporting methodology

This report was compiled by our management and reviewed and approved by our Directors. The 2019 UK Government Environmental Reporting Guidelines and the GHG Protocol Corporate Accounting and Reporting Standard (revised edition) (the "**GHG Protocol**") were followed to ensure the Streamlined Energy and Carbon Reporting ("**SECR**") requirements were met.

Energy data that relate to the Group were collated using existing reporting mechanisms. The energy data was converted to carbon emissions in accordance with the GHG Protocol. The associated emissions are divided into the combustion of fuels and the operation of facilities (scope 1), purchased electricity, heating and cooling (scope 2) and energy use and related emissions from (a) purchased goods and services and (b) business travel, including airfare, accommodations and certain ground transportation (scopes 3.1 and 3.6, respectively). For scope 2 emissions reporting, the Company used a market-based approach.

Carbon Emissions

The following sets forth scope 1, 2 and 3 (3.1 and 3.6) emissions related to the Group's employees, facilities and activities during 2024 and 2025:

tCO ₂ e	2024	2025
Scope 1	58	1,256
Scope 2	218	215
Scope 3	28,806	26,922
Total	<u>29,082</u>	<u>28,393</u>

Carbon Intensity

The chosen primary intensity ratio is total gross emissions in metric tonnes CO₂e per \$m turnover.

tCO ₂ e/\$m turnover	2024	2025
Carbon Emissions (Scope 1, 2 and 3), tCO₂e	29,082	28,393
Turnover, \$m	423	678
Carbon Intensity Ratio (tCO₂e/\$m turnover)	<u>69</u>	<u>42</u>

By geography:

Country	2024		2025	
	tCO ₂ e	% of Total Emissions	tCO ₂ e	% of Total Emissions
United States	17,846	61.4 %	18,912	66.6 %
South Korea	5,827	20.0 %	3,229	11.4 %
United Kingdom	2,716	9.3 %	3,091	10.9 %
Other	2,693	9.3 %	3,161	11.1 %
Total	<u>29,082</u>	<u>100 %</u>	<u>28,393</u>	<u>100 %</u>

Kiniksa Pharmaceuticals International, plc
Directors' report
For the year ended 31 December 2025

Energy Efficiency Actions for the year ended 31 December 2025

Energy efficiency is important to us. We regularly investigate ways to improve the efficiency of our offices and operations and, in the future, may implement strategies intended to curb our carbon emissions.

Financial risk management

The principal financial risks to which we are exposed are considered to be as follows:

Price Risk

Uncertainty exists as to the coverage and reimbursement status of any biological products for which we obtain regulatory approval. Payers, both public and private, may impose a number of restrictions or requirements prior to approving a therapy for patients. Further, the United States government and state legislatures and governments outside the United States have shown significant interest in implementing cost containment programs to limit the growth of government-paid healthcare costs, including price-controls, restrictions on reimbursement and requirements for substitution of generic products for branded drug and biologic products. We actively monitor coverage and reimbursement rates.

Credit Risk

Financial instruments that potentially subject us to concentrations of credit risk consist principally of cash, cash equivalents and short-term investments. As of 31 December 2025, substantially all of our cash, cash equivalents and short-term investments were held at two financial institutions. We generally maintain balances in various operating accounts at financial institutions that management believes to be of high credit quality, even if such amounts exceed federally insured limits. We have not experienced any losses related to our cash, cash equivalents and short-term investments and do not believe that we are subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.

We are also subject to credit risk from the accounts receivable related to product revenue. The majority of trade accounts receivable are recorded net of allowances for cash discounts associated with prompt payments from customers. All trade accounts receivable arise from product revenue in the United States due from our third party logistics provider. There were no material write-offs charged against the allowance for the year ended 31 December 2025.

Liquidity and cash flow risk

Our ability to generate product revenue sufficient to sustain and increase our corporate profitability will depend heavily on the continued commercialisation of ARCALYST and the development and eventual commercialisation of one or more of our current or future product candidates. In addition, payments and royalties arising from out-licensing, collaboration or other similar agreements, though potentially substantial, are often isolated events and cannot be relied upon to generate significant and sustained revenue. As such, a failure to execute on our core business strategy could materially affect our business and financial condition.

Kiniksa Pharmaceuticals International, plc
Directors' report
For the year ended 31 December 2025


Independent Auditor

PricewaterhouseCoopers has been Kiniksa International's auditor since its creation in 2024 and has served as the Group's auditor prior to the Redomiciliation since fiscal year 2016. The Audit Committee has appointed PwC as the independent registered public accountant to audit the financial statements of the Group and Kiniksa International for the fiscal year ended 31 December 2026, contingent on such appointment being approved by Kiniksa International's shareholders at the 2026 annual meeting of shareholders ("**AGM**"). PwC has expressed its willingness to continue in office as auditors for another year. In accordance with Section 489 of the Companies Act 2006, a resolution proposing that PwC be re-appointed as auditors of the Group and Kiniksa International will be proposed at the 2026 AGM.

Annual General Meeting

The Company's next AGM will be held on 20 May 2026. Further details were provided to Kiniksa International's shareholders via a separate proxy statement and notice of annual meeting.

This report was approved by the Board and signed on its behalf.

DocuSigned by:

9EFBEB991C8E4E0...

Sanj K. Patel

Director

Date: 19 March 2026

Kiniksa Pharmaceuticals International, plc
Directors' Remuneration Report
For the year ended 31 December 2025

Directors' Remuneration Report

Annual Statement from the Chair of the Compensation Committee

Dear Shareholders,

As the current Chair of the Compensation Committee (the "**Committee**") of the Board of Directors (the "**Board**") of Kiniksa International (including, as applicable, its predecessor entity, Kiniksa Pharmaceuticals, Ltd., and its consolidated subsidiaries), I am pleased to present, on behalf of the Board, the Directors' Remuneration Report for the year ended 31 December 2025 (the "**Remuneration Report**").

The Company's Remuneration Report and Directors' Remuneration Policy will be subject to an advisory vote at the forthcoming 2026 AGM on 29 May 2026.

Introduction

2025 was an exceptional year for Kiniksa. ARCALYST uptake in recurrent pericarditis grew throughout the year, with approximately 18% of the multiple-recurrence target population on active ARCALYST therapy as of the end of 2025 (compared to approximately 13% as of the end of 2024). Further, our team achieved ARCALYST net product revenue of \$677.6 million in 2025, representing 62% year-over-year growth. We also advanced our clinical portfolio, initiating our Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis, which we believe has the potential to offer monthly subcutaneous self-administration in a liquid formulation. We believe that such a drug, if approved, could expand the recurrent pericarditis market by offering an additional treatment option for recurrent pericarditis patients. Further, we have continued our pre-clinical work on KPL-1161 and expect to initiate a Phase 1 first-in-human trial by the end of 2026. Further, our organization has maintained a strong financial position that we believe will enable additional value-creating opportunities in the future. At Kiniksa, our goal is first and foremost to deliver life-changing therapies to patients with unmet medical needs and it is through the guidance of our Board and performance of our executive team that we aim to do so.

As a Nasdaq listed biopharmaceutical company with operations across the world, we operate within a global marketplace for talent. This market is competitive, especially in the United States where the bulk of our workforce is located. The Committee, with assistance from its independent compensation consultant, references the United States market as the leading indicator for healthcare remuneration levels and practices. Its goal is to attract and retain leading executive talent that can deliver on our goals to provide long-term, sustainable growth for our shareholders and life-changing therapies to our patients.

The Committee additionally considers other compensation frameworks, including guidance from proxy advisory firms, our investors and the principles of the UK Corporate Governance Code, when making decisions on director and executive compensation.

Key Decisions and Activities in the Year Ended 31 December 2025

In the year ended 31 December 2025, the Committee has undertaken the following key decisions and activities:

- Implemented a long-term incentive plan (the "**KPL-387 LTIP**") underneath the 2018 Plan (as defined below) pursuant to which cash awards, PSUs (as defined below) and performance share options "**PSOs**") were granted to our employees, including the Executive Director, to incentivize development and eventual commercialization of KPL-387;

Kiniksa Pharmaceuticals International, plc
Directors' Remuneration Report
For the year ended 31 December 2025

- Considered the Company's achievement of its 2025 corporate goals, and determined the applicable bonus payout for the Executive Director and the Company's executive leadership team;
- Considered input from the Committee's independent compensation consultant, as well as listened to feedback from proxy advisory firms and our investors, to set the pay levels for the Executive Director, the non-Executive Directors, and the Company's executive leadership team;
- Worked with the Committee's independent compensation consultant to review and update the Company's compensation peer group;
- Assessed the independence and suitability of the Company's independent compensation consultant;
- Served as administrator of the Company's equity incentive programs, including the 2018 Employee Share Purchase Program (the "**ESPP**"), 2015 Equity Incentive Plan (the "**2015 Plan**") and the 2018 Equity Incentive Plan (including, as applicable its UK Sub-Plan, the "**2018 Plan**") and assessed the anticipated adequacy of share reserves under such equity incentive programs; and
- Setting the Policy (as defined below).
- Reviewed and approved the Company's biannual grant of share options and restricted share units ("**RSUs**") to its employees;
- Reviewed and approved the annual grant of performance share units ("**PSUs**") to the Company's senior executive leadership team;
- Considered and approved awards of share options and RSUs to newly hired employees at or above the VP-level and delegated authority to the Executive Director to make awards of share options and RSUs to the Company's other newly hired employees; and
- Reviewed the Committee's charter and recommended changes to the Board for approval.

A Summary of Substantial Changes Relating to Directors' Remuneration During the Year

As part of its duties, the Committee regularly consults prevailing market compensation practices and makes necessary adjustments to our Directors' remuneration packages. Beginning in 2024, the Committee introduced PSUs to the Executive Director's long-term equity incentive award remuneration in order to further align our Executive Director's interests with that of our shareholders. In 2025, the Committee implemented PSOs as part of the KPL-387 LTIP in order to add an additional performance-based compensation element to our Executive Director's pay mix. In addition, in January 2026, the Committee reviewed and approved increases to our Non-Executive Directors' equity remuneration, which we believe will offer a competitive pay package compared to our compensation peer group and industry. Further details can be found below under "Proposed Application of the Policy for the Year Ending 31 December 2026".

**Kiniksa Pharmaceuticals International, plc
Directors' Remuneration Report
For the year ended 31 December 2025**

This has been a momentous year for the Company and its employees. We hope you find the information in this report helpful. There will be an opportunity to address any questions you may have at the 2026 AGM.

Yours gratefully,

A handwritten signature in black ink, reading "Kimberly J. Popovits". The signature is written in a cursive style with a large initial 'K' and 'P'.

Kimberly Popovits
Chair of the Committee
19 March 2026

**Kiniksa Pharmaceuticals International, plc
Directors' Remuneration Report
For the year ended 31 December 2025**

Remuneration Policy

The information provided in this part of the Directors' Remuneration Report is not subject to audit.

This part of the Remuneration Report sets out the Company's Directors' Remuneration Policy (the "**Policy**"), which will be submitted for shareholder approval in a binding vote at the 2026 AGM, to be held on 29 May 2026 and, if approved, will replace the Directors' Remuneration Policy approved at the Company's 2025 AGM. The only changes, as outlined below, are to the value of subsequent awards given to our non-Executive Directors. There were no changes to our compensation policies with respect to our Executive Director.

If approved, the Policy will be effective from the date of the 2026 AGM for a maximum of three years, or until a revised policy is approved by shareholders. There will continue to be an advisory vote on the Directors' Remuneration Report presented at our AGMs on an annual basis.

Overview of Policy

The Policy set out herewith will apply to our:

- Employee Directors appointed to the Board ("**Executive Directors**"); and
- Non-Employee Directors appointed to the Board ("**Non-Executive Directors**").

Currently, our Chairman and Chief Executive Officer, Sanj K. Patel, is the only Executive Director on the Board. However, the Policy will apply equally to any additional Executive Directors who may be appointed to the Board in the future. All other Directors currently serving on our Board are Non-Executive Directors. The other executive officers of the Company for whom we report remuneration information in our filings with the SEC are not subject to the Policy and are not required to be reported on as part of the Directors' Remuneration Report except for the period of time in the year ended 31 December 2024 where certain of our executive officers temporarily served as Directors prior to the Redomiciliation.

Summary of Policy – Executive Directors

The Policy, as it applies to Executive Directors, is designed to attract and retain Executive Directors and motivate them to enhance long-term shareholder value. The Policy is designed to reward and drive both short-term and long-term performance, mitigate against undue risk and align the financial interests of our Executive Directors with those of our shareholders. As a United States-centered business with senior executives based in the United States, the Policy reflects remuneration practices in the United States, which we believe will help the Company compete effectively in its primary market for talent.

The primary elements of the Policy applicable to the Executive Director are base salary, annual performance bonuses and long-term equity-based compensation awards. Our Executive Director is also eligible to participate in employee benefit plans and programs that we offer to our executive officers and full-time employees on the same basis, including participation in our retirement plan. We believe the Policy strikes an appropriate balance between the implementation of responsible, measured remuneration practices and the effective provision of incentives for our Executive Director to exert his best efforts for our success.

The Committee reviews and approves, or recommends to the Board for approval, the remuneration of the Executive Director on an annual basis. As part of its review, the Committee reviews corporate goals and objectives relevant to the remuneration of the Executive Director and evaluates the performance of the Executive Director in light of such goals and objectives. In addition, the Committee reviews whether any changes to the Policy are required, taking into account the needs of the Company and the evolving state of its

**Kiniksa Pharmaceuticals International, plc
Directors' Remuneration Report
For the year ended 31 December 2025**

competitive environment, while recognizing the need for remuneration practices to align with UK rules and regulations.

**Kiniksa Pharmaceuticals International, plc
Directors' Remuneration Report
For the year ended 31 December 2025**

The policy table set out below describes the Company's proposed future remuneration policy for the Executive Director and explains how each element of the remuneration packages will operate.

Purpose and Link to Strategy	Operation	Maximum	Performance Targets
<p>Base Salary</p> <p>Base salary is intended to provide a fixed component of remuneration reflecting the Executive Director's skill set, experience, role and responsibilities. The base salary for the Executive Director, as for other members of senior management, has generally been set at levels deemed necessary to attract and retain such individuals.</p>	<p>The Committee reviews and approves, or recommends to the Board for approval, the base salary of the Executive Director each year. As part of its review, the Committee reviews the Company's corporate goals and objectives relevant to the remuneration of the Executive Director and evaluates the individual performance of the Executive Director in light of such goals and objectives. The Committee additionally consults prevailing market practice among the Company's compensation peer group (composed primarily of US biotechnology companies with similar portfolios, commercial operations and/or market capitalization) and within the Company's industry with respect to compensation matters. The Committee retains discretion to adjust the base salary of the Executive Director as necessary to attract and retain such individual, or in conjunction with any changes to</p>	<p>There is no prescribed maximum level of base salary or annual salary increase. In determining any annual base salary, including any increase to base salary, the Committee will consider the factors set out under "Operation".</p>	<p>None.</p>

**Kiniksa Pharmaceuticals International, plc
Directors' Remuneration Report
For the year ended 31 December 2025**

Purpose and Link to Strategy	Operation	Maximum	Performance Targets
Annual Cash Incentive Remuneration			
<p>We offer our Executive Director the opportunity to earn an annual performance bonus to compensate him for attaining short-term company goals as approved by our Committee and/or Board relating to our overall business and strategy and for his individual performance. The annual performance bonus is paid entirely in cash.</p>	<p>Our Executive Director is eligible to earn an annual cash bonus at a specified target bonus opportunity, as established by the Committee, with the actual bonus paid determined by the Committee based on achievement of corporate and individual performance targets.</p> <p>Annual corporate performance goals are reviewed by the Committee and the Board each year, with performance assessed against such objectives at the end of the year. In approving the corporate performance goals each year, the Committee endeavors to set goals that are reasonably achievable with strong performance by the Company.</p> <p>Corporate goals are weighted by the Committee in proportion to their degree of importance for the Company. Based upon the Company's performance against such goals, the Committee will</p>	<p>There is no formal maximum to the amount that may be paid to the Executive Director as part of his annual bonus.</p> <p>In 2025, the target bonus of our Executive Director was 75% of his base salary. The Committee retains ultimate discretion over the final payout and may award an annual cash bonus above or below this target based upon its evaluation of the Executive Director's and Company's annual performance.</p> <p>While there is not a defined maximum amount of cash bonus that can be approved by the Committee, it exercises discretion to approve bonus payouts reasonable in the context of individual and overall company performance and historically above-target payouts have not exceeded 200% of target bonus.</p>	<p>Each year the Committee reviews with management the corporate goals by which the Company's performance will be assessed. Such goals are tailored to the Company's position, needs and strategy for a given year, though recurring goals include those related to commercial and clinical performance.</p> <p>In 2025, the Committee assessed the performance of the Executive Director against corporate goals related to commercial execution, research and development, business development, compliance and capital preservation as part of its assessment of annual bonus payouts. Details of such analysis are provided elsewhere in this Directors' Remuneration Report, subject to non-prejudicial and/or commercially sensitive information, including</p>

**Kiniksa Pharmaceuticals International, plc
Directors' Remuneration Report
For the year ended 31 December 2025**

Purpose and Link to Strategy	Operation	Maximum	Performance Targets
	<p>make a decision as to the Executive Director's bonus payout.</p>		<p>the weighting applied to each goal by the Committee. The Committee has determined that due to such prejudicial and/or commercial sensitivity, it will not disclose such information now or ever.</p>

Equity Incentive Awards

<p>Equity awards align the interests of our Executive Director with long-term shareholder interests and help us to attract and retain employees.</p>	<p>Long-term equity incentive awards are granted to our employees, including the Executive Director, in connection with their hiring and have historically been granted on a biannual basis thereafter in accordance with the terms of the 2018 Plan. Biannual grants for the Executive Director include share options, RSUs and, beginning in 2024, PSUs.</p> <p>In addition, the Committee may periodically approve a specialized long-term equity incentive plan pursuant to the 2018 Plan for specific goals. In the year ended 31 December 2025, the Committee approved the KPL-387 LTIP, pursuant to which it granted cash awards, PSUs and PSOs to the Executive Director, in each case contingent on the achievement of</p>	<p>There is no specific maximum set for the grant of annual equity awards pursuant to the 2018 Plan and, as the administrator of the 2018 Plan, the Committee reserves discretion to determine the types and terms of equity awards granted pursuant thereto, including the size and timing of equity grants.</p> <p>When making award determinations pursuant to the 2018 Plan, the Committee will take into account the underlying financial and operational performance of the Company, prevailing practices of the Company's compensation peer group, potential shareholder dilution caused by grants of equity awards and individual performance by the Executive Director. As a general practice, the Committee endeavors to provide the Executive Director with long-term equity award</p>	<p>Performance conditions are not typically attached to the vesting of share options or time-based RSUs. Instead, options and RSUs vest over time, pursuant to the terms of the relevant equity award agreement.</p> <p>For PSUs granted to the Executive Director on an annual basis, performance metrics consist of commercial performance and total shareholder return. For cash awards, PSUs and PSOs granted pursuant to the KPL-387 LTIP, performance metrics consisted of milestones related to the submission of a biologics license application and receipt of FDA marketing approval, in each case, for KPL-387 for the treatment of recurrent pericarditis. Specifics of such</p>

**Kiniksa Pharmaceuticals International, plc
Directors' Remuneration Report
For the year ended 31 December 2025**

Purpose and Link to Strategy	Operation	Maximum	Performance Targets
<p>milestone goals as described under "Performance Targets".</p> <p>Share options granted to the Executive Director generally vest and become exercisable as to 25% of the shares underlying the option on the first anniversary of the date of grant and in 36 equal monthly installments thereafter, subject to the Executive Director's continued service to the Company. RSUs granted to the Executive Director generally vest as to 25% of the RSUs on each of the first, second, third and fourth anniversaries of the date of grant, subject to the Executive Director's continued service to the Company. PSUs granted to the Executive Director on an annual basis vest after three years with the shares issuable thereto determined based upon performance metrics selected by the Committee at the time of grant. Specialized grants, such as the cash awards, PSUs and PSOs granted pursuant to the KPL-387 LTIP vest, in each case, pursuant to the terms contained in the applicable grant agreement.</p> <p>In addition, the Company maintains the ESPP, which the Executive</p>	<p>remuneration with a fair market value (at the date of determination) at the approximately 60th percentile of the fair market value of equity awards granted to chief executive officers in the Company's compensation peer group, as adjusted in light of the other factors discussed in the foregoing sentence. As described below, the compensation peer group is composed of companies with similar characteristics as the Company, which the Committee believes to be a fair representation of applicable market practice for the remuneration of our Directors.</p> <p>The grant date fair market value of equity awards granted to the Executive Director has historically never exceeded 800% of the value of his then-current annual base salary.</p> <p>At the time of its initial public offering in 2018, which coincided with the adoption of the 2018 Plan, the Company reserved 4,466,500 shares under the 2018 Plan. The 2018 Plan provides that the number of shares reserved and available for issuance under the plan will automatically increase each</p>	<p>performance targets, including achievement thresholds, is considered by the Committee to be prejudicial and/or commercially sensitive information. The Committee has determined that due to such prejudicial and/or commercial sensitivity, it will not disclose such information now or ever.</p>	

**Kiniksa Pharmaceuticals International, plc
 Directors' Remuneration Report
 For the year ended 31 December 2025**

Purpose and Link to Strategy	Operation	Maximum	Performance Targets
	<p>Director is eligible to participate in on the same terms as other employees.</p>	<p>January 1, beginning on 1 January 2019 and ending on and including 1 January 2028 by an amount equal to 4% of the aggregate number of shares outstanding (on an as-converted basis) on the final day of the immediately preceding calendar year or such smaller number of shares as determined by the Board.</p>	
		<p>The ESPP generally allows the Executive Director to save a portion (up to \$25,000 per year) of his salary over a six-month savings period. At the end of the savings period, Class A Shares are automatically purchased at the lower of the closing price of the shares at the day of enrollment or day of purchase for that particular period, minus a 15% discount. The ESPP provides that the number of shares reserved and available for purchase under the plan will automatically increase each 1 January, beginning on 1 January 2019 and ending on and including 1 January 2028 by an amount equal to 1% of the aggregate number of shares outstanding (on an as-converted</p>	

**Kiniksa Pharmaceuticals International, plc
 Directors' Remuneration Report
 For the year ended 31 December 2025**

Purpose and Link to Strategy	Operation	Maximum	Performance Targets
		basis) on the final day of the immediately preceding calendar year or such smaller number of shares as determined by the Board.	
		As of 31 December 2025, there were 5,621,352 Class A shares and 690,063 Class A shares available for future grants under the 2018 Plan and the ESPP, respectively.	

Retirement Plan

We believe our retirement plan enhances the overall desirability of our remuneration package for our Executive Director and further incentivizes him by providing a vehicle for tax-deferred retirement savings.

Our Executive Director, who is based in the United States, is eligible to join a 401(k) retirement savings plan on the same terms as other full-time employees.

The Executive Director is eligible to receive a Company match consisting of (a) 100% of the first 3% of his salary contributed, plus (b) 50% of the next 2% of his salary contributed.

The maximum contribution under the Company's 401(k) program is 4% of an employee's cash remuneration, subject to statutory limitations on 401(k) plan contributions.

None.

Benefits

We provide market competitive, yet cost-effective employment benefits to the Executive Director in order to enhance the overall desirability of our remuneration package for him.

Our Executive Director is eligible to participate in our health and welfare plans, including medical, dental and vision benefits, a healthcare flexible spending account, a dependent care flexible spending account,

There is no formal maximum level of benefits provided to the Executive Director, as the value of each benefit is not predetermined and is typically based upon the cost to the Company of providing said

None.

**Kiniksa Pharmaceuticals International, plc
Directors' Remuneration Report
For the year ended 31 December 2025**

Purpose and Link to Strategy	Operation	Maximum	Performance Targets
	<p>short-term and long-term disability insurance and life insurance to the same extent as our other full-time employees generally, subject to the terms and eligibility requirements of those plans.</p> <p>The Committee reviews benefits offered from time to time and retains discretion to add or substitute benefits to ensure they remain market competitive.</p>	<p>benefit, which will vary from year to year based on costs incurred from third-party providers.</p>	

**Kiniksa Pharmaceuticals International, plc
Directors' Remuneration Report
For the year ended 31 December 2025**

Policy on Payments for Loss of Office – Executive Director

Sanj K. Patel, our Chairman and Chief Executive Officer, is currently our only Executive Director. Under the terms of his employment agreement, if Mr. Patel's employment with us is terminated as a result of his death or disability, by the Company without cause, or by Mr. Patel for good reason, whether or not in connection with a change in control, he will be entitled to receive (a) a lump sum payment equal to (i) 200% of the sum of his annual base salary and target bonus for the year of termination plus (ii) \$25,000, (b) a prorated portion of his target bonus for the year of termination and (c) any earned, but unpaid, cash annual bonus for the year prior to the year of termination.

If such termination of employment occurs other than during the 12-month period following a change in control, Mr. Patel will be entitled to accelerated vesting of all of his then-unvested time-vesting equity that would have, absent termination, become vested within 18 months following such termination of employment. For avoidance of doubt, any time-vesting equity that would have, absent termination, become vested more than 18 months following the termination will not be entitled to acceleration. If such termination of employment occurs during the 12-month period following a change in control, Mr. Patel will be entitled to full accelerated vesting of all of his then-unvested time-vesting equity. Pursuant to the award agreements governing the terms of Mr. Patel's currently outstanding annually granted PSUs, if Mr. Patel's employment is terminated for "good reason," such PSUs will remain outstanding and become eligible to become earned in accordance with such award agreement, with any earned PSUs prorated based on the number of days Mr. Patel was in office during the performance period. Under the terms of the KPL-387 LTIP, if Mr. Patel is terminated without cause or if Mr. Patel terminates his employment for "good reason" and, within 60 days of the date of termination, the BLA Acceptance Date (as defined in the KPL-387 LTIP) occurs, Mr. Patel will be deemed employed on such date for purposes of the applicable awards.

Mr. Patel's right to receive these severance payments and benefits is subject to his execution and non-revocation of a release of claims for the benefit of Kiniksa and his compliance with certain confidentiality obligations and restrictive covenants.

In the event of a change in control, Mr. Patel will become immediately vested in each outstanding time-vesting equity award granted to him that is not assumed or substituted for in the change in control transaction.

In addition to the above, the Board reserves the right to make such additional severance payments, if any, with respect to the termination of an Executive Director that it considers reasonable under the individual circumstances. We will comply with applicable disclosure and reporting requirements of the SEC with respect to remuneration arrangements with a departing Executive Director.

Remuneration on Recruitment

The remuneration package for any new Executive Director will be determined by the Committee in accordance with the terms of the Policy at the time of appointment (including base salary, annual performance target bonus, long-term equity-based compensation awards, retirement plans and benefits). It is recognized that in order to attract and recruit talented individuals, the Policy must allow sufficient flexibility with respect to remuneration on recruitment, and the Committee has reserved discretion to make special provisions tailored to the recruiting situation, including with respect to a potential sign-on bonus, reasonable relocation support and make-whole arrangements for remuneration forfeited from a prior employer (whether on account of cash bonuses, share awards, pension benefits or other forfeited items).

The remuneration package for any new Non-Executive Director will be set in accordance with the terms of our Non-Employee Director Compensation Program, as described below.

**Kiniksa Pharmaceuticals International, plc
Directors' Remuneration Report
For the year ended 31 December 2025**

Compensation Peer Group

Market practices are one of the considerations taken into account by the Committee when determining Director remuneration. In determining compensation, the Committee may peg all or a portion of our Remuneration to a particular percentile of the compensation peer group for a given year, however the Compensation Committee has and will adjust such target percentiles as needed or desired.

In order to ensure our remuneration is competitive the Committee, with the assistance of Compensia, maintains and annually updates a group of peer companies with which to benchmark Director compensation. The Compensation Committee reviews the information provided from internal sources as well as the information provided by Compensia to select our peer group based on comparable biopharmaceutical companies.

For the compensation peer group approved for 2025, the Committee considered the following criteria when selecting peer companies:

- Primary Criteria
 - *Industry*: Companies must be either biotechnology or pharmaceutical companies.
 - *Market Capitalization*: Companies must have a 30-day average market capitalization of approximately 25% to 400% of Kiniksa's 30-day average market capitalization.
 - *Stage of Lead Drug*: Companies must be in Phase III development or pending regulatory approval for their lead product candidate or commercializing a drug product.
- Refinement Criteria
 - *Revenue*: Annual product revenue of approximately \$100 million to \$1 billion.
 - *Indication*: Primary indications for the company's development portfolio must be auto-immune, auto-inflammatory, cardiovascular and/or rare disease.
 - *Pipeline*: Must have two or more programs in the company's development pipeline.
- Additional Considerations
 - *Geography*: US-based companies located outside the San Francisco Bay Area, with a preference for Massachusetts-based companies.
 - *Reverse Peers*: Companies that have named Kiniksa as a peer company.
 - *Peers of Identified Companies*: Companies that are peers of certain specified peers of interest.

**Kiniksa Pharmaceuticals International, plc
Directors' Remuneration Report
For the year ended 31 December 2025**

The 2025 compensation peer group (in alphabetical order) was as follows:

Kiniksa 2025 Compensation Peer Group	
Acadia Pharmaceuticals	Agios Pharmaceuticals
Amicus Therapeutics	Apellis Pharmaceuticals
Arcutis Biotherapeutics	Ardelyx
BioCryst Pharmaceuticals	Blueprint Medicines
BridgeBio Pharma	Collegium Pharmaceutical
Corcept Therapeutics	Harmony Biosciences Holdings
Ironwood Pharmaceuticals	Macrogenics
Rhythm Pharmaceuticals	Sage Therapeutics
Supernus Pharmaceuticals	Traverse Therapeutics
Ultragenyx Pharmaceutical	Vericel

At the time our 2025 compensation peer group was approved in August 2024, our market capitalization was at approximately the 56th percentile of the peer group and our last four quarters' revenue was at approximately the 51st percentile of the peer group.

Compensation Recovery Policy

The Company maintains a Policy for the Recovery of Erroneously Awarded Compensation designed to comply with the mandatory compensation "clawback" requirements under Nasdaq rules. Under this policy, which applies to the Executive Director, in the event of certain accounting restatements, we will be required to recover erroneously awarded incentive compensation tied to a financial reporting measure (including measures related to share price and total shareholder return).


The amount of erroneously awarded compensation to be recovered shall equal the excess of the amount actually received over the amount that would have been received had the financial statements been correct in the first instance. Where the financial reporting measure is related to share price or total shareholder return, the Committee shall make a reasonable estimate of the effect of the accounting restatement upon the share price or total shareholder return and the amount of the compensation to be recovered. The Committee has discretion as to the method for recovering erroneously awarded compensation from the Executive Director, in the event of an accounting restatement.

A portion of our Executive Director's annual bonus is based upon the achievement of certain commercial performance goals. In addition, certain of our Executive Director's outstanding PSUs are based on commercial performance and total shareholder return metrics.

**Kiniksa Pharmaceuticals International, plc
Directors' Remuneration Report
For the year ended 31 December 2025**

Application of the Remuneration Policy to Executive Director Remuneration for the Year Ending 31 December 2026

The chart below shows an estimate of the 2026 remuneration package for the CEO (our sole Executive Director) under three assumed performance scenarios, based on the Policy.



The minimum scenario comprises (a) the CEO's salary, (b) the value of benefits, (c) the value of Company 401(k) matching contributions and (d) the expected market value of RSUs to be granted in the year ended 31 December 2026, which are earned regardless of performance. For more information on the valuation methodology of our long-term equity awards, including RSUs, see footnote (1) to the Single Total Figure of Remuneration Table below.

The target scenario comprises the pay set out under the minimum scenario, plus (a) a cash bonus payout at target, consisting of 75% of salary and (b) the value of PSUs to be granted in the year ended 31 December 2026 as if they had vested at the target level of 100% within such year.

The maximum scenario comprises the pay set out under the minimum scenario, plus (a) an illustrative cash bonus payout at 150% of the CEO's salary and (b) the value of PSUs to be granted in the year ended 31 December 2026 as if they had vested at the maximum level of 200% within such year. While there is not a defined maximum amount of cash bonus that can be approved by the Committee, it exercises discretion to

**Kiniksa Pharmaceuticals International, plc
Directors' Remuneration Report
For the year ended 31 December 2025**

approve bonus payouts reasonable in the context of individual and overall company performance and historically above-target payouts have not exceeded 200% of target bonus.

The maximum scenario with a share price increase comprises the pay set out under the maximum scenario as adjusted by (a) including the market price of share options granted in the year ended 31 December 2026 as if the price of our Class A Shares had increased by 50% from the date of grant, (b) the value of PSUs to be granted in the year ended 31 December 2026 as if they had vested at the maximum level of 200% within such year and the price of our Class A Shares had increased by 50% from the date of grant and (c) the value of RSUs to be granted in the year ended 31 December 2026 as if the price of our Class A Shares had increased by 50% from the date of grant.

In each of the above scenarios, the face value of the equity awards used was \$44.39, which is the 30-day trailing average price used to compute Mr. Patel's 2026 long-term equity award grants.

Summary of Policy –Non-Executive Directors

We maintain a program (the "**Non-Employee Director Compensation Program**"), which governs the fees and equity awards payable to Non-Executive Directors. Such policy is periodically reviewed by the Committee, which recommends any changes to the Board for approval. The Committee and Board reserve discretion to recommend and approve, respectively, changes to the Non-Employee Director Compensation Program consistent with the duties and obligations of the Directors and in line with market practice.

Non-Executive Directors typically receive an annual retainer paid in cash for their service (depending on their additional membership and chairperson responsibilities with respect to the Board's committees) and an annual grant of equity awards, but they do not receive any performance-based incentive component of remuneration. There are no elements of the Non-Employee Director Compensation Program that are subject to performance conditions, and accordingly there are no provisions for the recovery or withholding of sums.

**Kiniksa Pharmaceuticals International, plc
Directors' Remuneration Report
For the year ended 31 December 2025**

The policy table set out below describes our Non-Employee Director Compensation Program and explains how each element of the remuneration package for Non-Employee Directors operates. In addition, per our Articles of Association, our Directors, including our Non-Executive Directors, may be reimbursed for all reasonable transportation, hotel and other expenses properly incurred by them in the conduct of the Company's business performing their duties as Directors, including in connection with attending and returning from meetings of the Board or any committee of the Board.

Purpose and link to strategy	Operation	Maximum
<p>Cash Component Cash retainers for Non-Executive Directors are intended to attract and retain high caliber individuals with the requisite experience and knowledge to oversee and advise our Company.</p>	<p>Each Non-Executive Director receives an annual retainer of \$50,000 for service on the Board. A Non-Executive Director serving as Chairperson of the Board (or Lead Independent Director in the event that the Chairperson is an Executive Director) is entitled to an annual retainer of \$30,000 for such service, which retainer is in addition to any other fees to which such Non-Executive Director would be entitled.</p>	<p>None</p>
<p>Non-Executive Directors are also entitled to additional annual retainers in connection with their service on the committees of the Board. The chairperson of each committee is entitled to an additional annual cash retainer in connection with such service.</p>		
<p>Non-Executive Directors' annual fees are set forth in the Company's Non-Employee Director Compensation Program. Detailed information related to amounts payable to Non-Executive Directors, including fees payable for particular committee assignments, are as follows:</p>		

**Kiniksa Pharmaceuticals International, plc
 Directors' Remuneration Report
 For the year ended 31 December 2025**

Board Position	Cash Retainer
Director	\$50,000
Chair or Lead Independent Director	\$30,000
Audit Committee Chair	\$20,000
Compensation Committee Chair	\$20,000
Nominating and Corporate Governance Committee Chair	\$10,000
Science and Research Committee Chair	\$20,000
Audit Committee Member	\$10,000
Compensation Committee Member	\$9,000
Nominating and Corporate Governance Committee Member	\$5,000
Science and Research Committee Member	\$9,000

Purpose and link to strategy

Operation

Maximum

These amounts are periodically reviewed by the Committee, taking into account the Company's compensation peer group and overall market practice.

In addition, Non-Executive Directors may be appointed to one or more ad hoc committees as the need arises. In the year ended 31 December 2024, the Board formed a Strategic Transaction Committee, whose members were entitled to receive an annual fee of \$6,300, pro-rated for the number of days that the committee was in existence.

Equity Component

Equity awards align the interests of our Non-Executive Directors with long-term shareholder interests and help us attract and retain qualified individuals to served on our Board.

None.

We grant equity awards, consisting of share options and RSUs, to our Non-Executive Directors in order to align their interests with those of our shareholders. Non-Executive Directors' initial and annual equity grants are set forth in the Company's Non-Employee Director Compensation Program. Initial grants are awarded on the date of the Non-Executive Director's appointment and annual equity grants are granted on the date of each year's AGM. For the year ended 31 December 2026, (a) the value of initial grants for each Non-Executive Director was increased from \$600,000 to \$700,000 and (b) the value of annual grants for each Non-Executive Director was increased from \$340,000 to \$400,000, in each case subject to our shareholders' approval at the 2026 AGM.

The share options granted upon a Non-Executive Director's initial election or appointment vest and become exercisable (a) as to one-third of the shares on the first anniversary of the date of grant and (b) as to the remainder in twenty-four substantially equal monthly installments thereafter, generally subject to the Non-Executive Director

**Kiniksa Pharmaceuticals International, plc
Directors' Remuneration Report
For the year ended 31 December 2025**

Purpose and link to strategy **Operation** **Maximum**

continuing in service through the applicable vesting date. The share options granted annually to Non-Executive Directors vest and become exercisable in twelve substantially equal monthly installments following the date of grant, with the last installment vesting on the earlier of (a) the anniversary of the date of grant or (b) the date of the AGM in the following year, generally subject to the director continuing in service through the applicable vesting date.

RSUs granted to our Non-Executive Directors under the program vest (a) as to initial awards, as to one-third of the RSUs subject to such award on each anniversary of the date of grant and (b) as to subsequent awards, as to 100% of the RSUs subject to such award on the earlier of (i) the anniversary of the date of grant or (ii) the date of the AGM in the following year, generally subject in each case to the Non-Executive Director continuing in service through the applicable vesting date.

Equity awards issuable to Non-Executive Directors, on appointment and annually thereafter, is as follows:

	Equity Award ⁽¹⁾⁽²⁾
Initial Award	\$700,000
Subsequent Award	\$400,000

(1) Reflects equity award values as approved by the Committee and the Board following 31 December 2025, subject to our shareholders' approval at our 2026 AGM.

(2) Award reflects such value, divided by the Black-Scholes value of a Class A Share, rounded down to the nearest whole share. Such grants shall not exceed 93,300 Class A Shares with respect to Initial Awards and 53,600 Class A Shares with respect to Subsequent Awards.

Purpose and link to strategy **Operation** **Maximum**

Other Remuneration

To compensate Non-Executive Directors who provide services over and above those expected for their position.

From time to time, we may enter into additional compensatory arrangements with our Non-Executive Directors in connection with the provision of services beyond the typical scope of their service. Such compensatory arrangements will be reviewed and approved by the Committee and the Board, with the interested Non-Executive Director abstaining from such review and approval.

None.

**Kiniksa Pharmaceuticals International, plc
Directors' Remuneration Report
For the year ended 31 December 2025**

The foregoing is qualified in its entirety by the Company's current Non-Employee Director Compensation Program, as may be amended from time to time.

**Kiniksa Pharmaceuticals International, plc
Directors' Remuneration Report
For the year ended 31 December 2025**

Policy for the Chair

The position of Chairperson of the Board is currently held by our CEO. So long as the position of Chairperson is held by an employee of the Company, it is not entitled to any fees owing to such title. Such fees, currently \$30,000, will instead be payable to a Non-Executive Director designated as our Lead Independent Director. In the event that the position of Chairperson is held by a Non-Executive Director, the Company would compensate the Chairperson for their role and services as set forth in our Non-Executive Director Compensation Program, which is outlined above.

Policy for Service

The Company does not maintain employment contracts or letters of appointment with our Non-Executive Directors. Instead, in accordance with the Company's Articles of Association, Non-Executive Directors are elected by the Company's shareholders for a three-year term of office, and successors to the class of Directors whose term expires at a given AGM are elected for a subsequent three-year term. Non-Executive Directors may resign at any time, with their vacancy to be filled by the remaining Directors, and any Director so appointed shall hold office only until the next following annual general meeting. Non-Executive Directors do not have any notice periods prior to termination of service and are not generally entitled to any compensation on termination. However, immediately prior to any Change of Control event (as defined in the 2018 Plan), all outstanding option awards and RSU awards previously granted to a Non-Executive Director shall vest in full, to the extent outstanding at such time. The Committee also reserves the right to accelerate vesting of any unvested equity awards upon the resignation or termination of a Non-Executive Director.

Legacy Arrangements

For the duration of this Policy, the Company will honour any remuneration and/or severance commitments made in respect of current or former Directors before the date on which either (a) the Policy becomes effective; or (b) an individual becomes a Director, even where not consistent with the Policy set out in this report or prevailing at the time such commitment is fulfilled. Details of any payments to former Directors will be set out in the annual Directors' Report on Remuneration as they arise. For the avoidance of doubt, all outstanding historic equity awards that were granted prior to the Policy's effective date remain eligible to vest based on their original terms.

Kiniksa Pharmaceuticals International, plc
Directors' Remuneration Report
For the year ended 31 December 2025

Statement of Consideration of Employees' Pay and Remuneration Conditions Elsewhere in the Group

The Committee periodically reviews with management the Company's strategies related to human capital management, including remuneration and benefits as they relate to the Company's talent acquisition and retention strategy. As appropriate, the Committee considers the pay and conditions of the broader employee workforce in the Group when making remuneration-related decisions for the Directors. However, no specific consultation with employees has been undertaken in respect of the design of the Company's Policy to date.

Statement of Consideration of Shareholder Views

The Board and Committee value the opinions of our shareholders. The Committee considered the outcome of the Company's non-binding, advisory vote on the remuneration of its named executive officers (the "Say-on-Pay" vote) when developing the Policy. The Policy was also approved by the full Board. The Committee also considers shareholder feedback, including the results of the Say-on-Pay vote, when evaluating the Company's remuneration policies and practices and making future remuneration decisions. The Company typically holds a Say-on-Pay vote annually in connection with its AGM.

**Kiniksa Pharmaceuticals International, plc
Directors' Remuneration Report
For the year ended 31 December 2025**

Annual Report on Remuneration

Single Total Figure of Remuneration of each Director (audited)

In the full year ended 31 December 2025, the Directors received the following remuneration (inclusive of remuneration paid prior to the Redomiciliation). Michael Megna, Ross Moat and Mark Ragosa served as Directors during the period from Kiniksa International's formation in April 2024 until the Redomiciliation. Remuneration for such individuals is included only for such periods. The base salary, benefits and retirement plan columns reflect the amount actually received during such service period. All other columns have a value of nil as no relevant compensation was received during such period.

Name	Year ending 31 December	Base Salary (\$)	Benefits (\$)	Bonus (\$)	Restricted Share Awards (\$ ⁽¹⁾)	Long-term Incentive Awards (\$ ⁽¹⁾)	Retirement Plan (\$) ⁽²⁾	Other (\$)	Total variable remuneration (\$)	Total fixed remuneration (\$)	Total Remuneration (\$)
Executive Directors											
Sanjiv K. Patel	2025	943,129	32,672 ⁽³⁾	1,284,065	3,798,021	—	14,000	—	5,082,086	989,801	6,071,887
	2024	899,371	32,417 ⁽⁴⁾	730,739	1,117,760	—	13,800	—	1,848,499	945,588	2,794,087
Michael Megna	2025	—	—	—	—	—	—	—	—	—	—
	2024	81,238	7,255 ⁽⁵⁾	—	—	—	2,451	—	—	90,944	90,944
Ross Moat	2025	—	—	—	—	—	—	—	—	—	—
	2024	111,650 ⁽⁶⁾	4,892 ⁽⁶⁾⁽⁷⁾	—	—	—	10,540 ⁽⁶⁾	—	—	127,082 ⁽⁶⁾	127,082
Mark Ragosa	2025	—	—	—	—	—	—	—	—	—	—
	2024	109,013	7,286 ⁽⁸⁾	—	—	—	2,987	—	—	119,286	119,286
Non-Executive Directors											
Felix J. Baker	2025	63,999	—	—	81,479	—	—	—	81,479	93,999	175,478
	2024	61,350	—	—	62,540	—	—	—	62,540	81,350	153,890
Stephen R. Bigger	2025	66,999	—	—	81,479	—	—	—	81,479	66,999	150,478
	2024	55,600	—	—	62,540	—	—	—	62,540	55,600	118,140
M. Carley Boyd	2025	99,000	—	—	81,479	—	—	—	81,479	59,000	140,479
	2024	11,575	—	—	115,790	—	—	—	115,790	11,575	127,365
G Bradley Cole	2025	59,999	—	—	81,479	—	—	—	81,479	59,999	141,478
	2024	49,000	—	—	62,540	—	—	—	62,540	49,000	111,540
Richard S. Levy	2025	89,998	—	—	81,479	—	—	59,991 ⁽⁹⁾	111,470	99,998	211,468
	2024	53,400	—	—	62,540	—	—	89,982 ⁽¹⁰⁾	107,522	98,400	205,922
Thomas R. Malley	2025	74,999	—	—	81,479	—	—	—	81,479	74,999	156,478
	2024	65,575	—	—	62,540	—	—	—	62,540	65,575	128,115
Tracey L. McClain	2025	59,999	—	—	81,479	—	—	—	81,479	59,999	141,478
	2024	49,000	—	—	62,540	—	—	—	62,540	49,000	111,540
Kimberly J. Popovits	2025	69,999	—	—	81,479	—	—	—	81,479	69,999	151,478
	2024	49,650	—	—	62,540	—	—	—	62,540	49,650	112,190
Barry D. Quant	2025	77,999	—	—	81,479	—	—	—	81,479	77,999	159,478
	2024	63,175	—	—	62,540	—	—	—	62,540	63,175	125,715
Non-Executive Director Total	2025	634,991	—	—	733,311	—	—	59,991	763,302	664,991	1,428,293
	2024	488,325	—	—	616,110	—	—	89,982	661,082	533,325	1,194,417
Total	2025	1,578,120	32,672	1,284,065	4,531,332	—	14,000	—	5,845,388	1,654,792	7,500,180
	2024	1,689,597	51,850	730,739	1,733,870	—	29,778	—	2,509,591	1,816,225	4,325,816

(1) The Directors receive market value share options as part of their remuneration with an exercise price equivalent to the closing price of our Class A Shares on the date of grant. These options are not subject to performance conditions. The Executive Director received PSOs in the year ended 31 December 2025 as part of the KPL-387 LTIP, which are subject to performance conditions and with an exercise price

**Kiniksa Pharmaceuticals International, plc
Directors' Remuneration Report
For the year ended 31 December 2025**

equivalent to the closing price of our Class A Shares on the date of grant. Granted PSOs are disregarded from the value of long-term equity awards in the year of grant and will instead be reflected in the value of long-term equity award remuneration in the year in which the applicable performance criteria are met, if at all. Refer to "Statement of Directors' Shareholder and Share Interests" below. The value of equity based awards in the form of RSUs is based on the market value of the underlying shares on the date of grant. Share price appreciation did not impact the value of awards. Granted PSUs are disregarded from the value of long-term equity awards in the year of grant and will instead be reflected in the value of long-term equity award remuneration in the year in which the applicable performance period ends.

- (2) Reflects Company matching contributions to the applicable person's 401(k) retirement plan and, in the case of Ross Moat only, contributions to a defined benefit pension plan.
- (3) Amount shown represents health insurance (health, dental and vision) (\$29,652) and life and disability insurance (\$3,020).
- (4) Amount shown represents health insurance (health, dental and vision) (\$29,560) and life and disability insurance (\$2,857).
- (5) Amount shown represents health insurance (health, dental and vision) (\$6,709) and life and disability insurance (\$546).
- (6) Original amount in GBP. Amount in table reflects such amount after applying a conversion from GBP to USD using the 2024 average FX rate (£1:\$1.277925).
- (7) Amount shown represents a car allowance. Mr. Moat did not receive insurance-related benefits during the covered period.
- (8) Amount shown represents health insurance (health, dental and vision) (\$6,709) and life and disability insurance (\$576).
- (9) Amount reflects (a) fixed remuneration of cash consulting fees (\$30,000) and (b) variable remuneration of the market value of fully vested RSUs (\$29,991), in each case provided in respect of his consulting services.
- (10) Amount reflects (a) fixed remuneration of cash consulting fees (\$45,000) and (b) variable remuneration of the market value of fully vested RSUs (\$44,982), in each case provided in respect of his consulting services.

**Kiniksa Pharmaceuticals International, plc
Directors' Remuneration Report
For the year ended 31 December 2025**

Annual Performance Bonus (audited)

For the year ended 31 December 2025, the annual bonus for our Executive Director was paid out at a rate of approximately 181% of his bonus target (75% of his base salary), or \$1,284,065, reflecting overall outstanding performance against the goals and metrics reviewed and approved by the Committee.

The Company's 2025 corporate goals are set forth below and reflect the Company's primary focus on executing its commercial strategy for ARCALYST while working to advance its portfolio of developmental assets. Details regarding the primary elements of each goal, its relative weighting, and the primary factors considered when the Compensation Committee considered the Company's performance against such goal are set forth below:

Goal	Weighting	Description of Primary Elements	Primary Factors Considered When Evaluating Performance
ARCALYST	55%	(a) Deliver on Arcalyst commercial performance, including net product revenue; and (b) Deliver on the objectives of the ongoing technology transfer of the ARCALYST drug substance manufacturing process, including (i) completing a process performance qualification campaign, (ii) maintaining the expected timeline towards FDA approval of Samsung Biologics Co., Ltd. ("Samsung") as the manufacturer of ARCALYST drug substance and (iii) maintaining adequate ARCALYST supply.	(a) The Company's commercial performance was well above expectations. In 2025, the Company initially guided to net product revenue of \$560-\$580 million. Over the course of 2025, the Company increased its ARCALYST net product revenue guidance three times and ultimately delivered net product revenue of \$677.6 million in 2025. The Company's strong commercial execution in 2025 resulted in a 62% growth in ARCALYST sales compared to 2024. (b) The Company continued to advance the technology transfer of the process for manufacturing ARCALYST drug substance. The Company successfully completed a number of process performance qualification runs with Samsung, maintained its expected timeline towards FDA approval of Samsung as the new ARCALYST drug substance manufacturer and ensured that the Company's clinical and commercial needs for ARCALYST were well-met.
The Committee considered this ARCALYST-focused objective to have been achieved far above target.			

**Kiniksa Pharmaceuticals International, plc
Directors' Remuneration Report
For the year ended 31 December 2025**

Goal	Weighting	Description of Primary Elements	Primary Factors Considered When Evaluating Performance
KPL-387	35%	(a) Initiate Phase 2/3 clinical trial with KPL-387; and (b) Advancing KPL-387 development towards a biologics license application filing.	(a) During 2025, the Company substantially completed its ongoing Phase 1 clinical trial of KPL-387 in normal, healthy volunteers. This work enabled the Company to submit an investigational new drug application for a Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis, which it initiated in 2025. (b) The Company's continued clinical development efforts have kept KPL-387 on-track towards its confidential target date for a biologics license application. Overall, the Company substantially advanced its KPL-387 development program, paving the way for a potential commercial launch of the drug. Given the rapid pace of development efforts, the Committee determined that this objective was met above target.
Advance Pre-Clinical Programs	5%	(a) Advance the Company's announced and unannounced pre-clinical assets	(a) The Company continued to advance both its public and confidential research and development candidates. With respect to KPL-1161, the Company's only public preclinical asset as of 31 December 2025, the Company identified a preclinical lead candidate, completed pre-clinical pharmacokinetics studies and initiated master cell bank production. The Committee determined that the Company met this goal at target.
Business Development	5%	Create opportunities for increasing corporate value, including (a) evaluating external business development transactions aligned with the Company's strategy and	This goal included activities beyond the scope of the Company's commercial and pipeline developmental functions.

**Kiniksa Pharmaceuticals International, plc
 Directors' Remuneration Report
 For the year ended 31 December 2025**

Goal	Weighting	Description of Primary Elements	Primary Factors Considered When Evaluating Performance
<i>and Corporate Structure</i>		vision for value generation and (b) initiating and running the partnering process for abiprubart.	<p>The Company's business development functions evaluated a number of opportunities, both transformational and value-additive, in 2025. While the Company did not announce any major transactions, it nonetheless met with, analyzed and negotiated a number of potential deals during the year. Further, the Company initiated a partnering process for abiprubart to identify a partner best able to unlock the value of the asset.</p> <p>Based on all of the above, the Committee determined that this goal was met at target.</p>

When evaluating the Company's achievement of its 2025 corporate goals, the Committee also considered the extent to which the Company remained compliant on conduct and ethics, value-driven, effective and well-capitalized. Such characteristics are fundamental to the Company's corporate values and necessary for the satisfactory accomplishment of its short- and long-term strategic vision. The Committee additionally considered the strategic development of the Company's intellectual property portfolio as necessary to protect its assets and whether the Company was able to attract and retain a talented team of employees. In 2025, the Committee viewed favorably the Company's ability to successfully accomplish its stated goals while adhering to its corporate values, retaining its workforce, protecting its assets, and weathering a turbulent market for US-based biopharmaceutical companies through smart capital allocation.

Kiniksa Pharmaceuticals International, plc
Directors' Remuneration Report
For the year ended 31 December 2025

Annual Restricted Share Awards and Long-Term Incentive Awards (audited)

In the year ended 31 December 2025, all Non-Executive Directors received grants of share options and RSUs in connection with our 2025 AGM. Dr. Levy received a grant of fully vested RSUs in connection with consulting services performed for the Company.

Our Executive Director received two grants of share options and RSUs in connection with our biannual awards to our employees, as well as a single grant of PSUs with metrics consisting of ARCALYST commercial performance and total shareholder return. The number of shares underlying long-term equity awards granted in a given year is set by the Committee in advance with reference to a value based on market data, industry practice and the need for retention and recognition of performance. Because the value of our Class A Shares may fluctuate between the time the Committee sets the award amount and the date of grant, such long-term equity awards may have a valuation either higher or lower than initially set.

The performance of granted PSUs are assessed by the Committee in following their three-year performance period (e.g., PSUs granted in 2025 are assessed in 2028), whereupon the total number of Class A Shares to be issued thereto will be determined, not to exceed 200% of the number of PSUs granted to the Executive Director.

Performance Share Awards and Long-Term Incentive Awards under the KPL-387 LTIP (audited)

In the year ended 31 December 2025, our Executive Director received grants of cash awards, PSUs and PSOs pursuant to the KPL-387 LTIP. Each award vests, if at all, upon the achievement of certain specified development and regulatory milestones and are subject to earnout percentages based upon the date of applicable milestone achievement.

Payments to Past Directors (audited)

During the years ended 31 December 2025 and 2024, no payments were made to past Directors.

Payments for Loss of Office (audited)

During the years ended 31 December 2025 and 2024, no payments were made to Directors for loss of office.

**Kiniksa Pharmaceuticals International, plc
Directors' Remuneration Report
For the year ended 31 December 2025**

Statement of Directors' Shareholder and Share Interests (audited)

The Company does not maintain share ownership guidelines for its officers or directors. The table below details the total number of shares owned (including their beneficial interests), the total number of share options held, the number of share options vested but not yet exercised, the total number of RSUs held and the total number of PSUs (assuming target performance) held as of 31 December 2025, as applicable.

Name	As-Converted Shares owned as of 31 December 2025	Share Options Owned as of 31 December 2025			RSUs Owned as of 31 December 2025	PSUs Owned as of 31 December 2025
		Total Share Options	Unvested Share Options	Vested but Unexercised Share Options		
Executive Directors						
<i>Sanj K. Patel</i>	1,747,749 ⁽¹⁾	2,941,864 ⁽²⁾	624,968	2,316,896	152,200	194,111 ⁽³⁾
Non-Executive Directors						
<i>Felix J. Baker</i>	31,702,828 ⁽⁴⁾⁽⁵⁾	181,591	8,398	173,193	2,799	—
<i>Stephen R. Biggar</i>	12,546	181,591	8,398	173,193	2,799	—
<i>M. Canteley Boyd</i>	1,577	45,182	25,743	19,439	5,952	—
<i>G. Bradley Cole</i>	12,546	163,276	8,398	154,878	2,799	—
<i>Richard S. Levy</i>	18,474	182,036	8,398	173,638	2,799	—
<i>Thomas R. Malley</i>	84,513 ⁽⁶⁾⁽⁷⁾	54,598	8,398	46,200	2,799	—
<i>Tracey L. McCain</i>	12,546	208,579	8,398	200,181	2,799	—
<i>Kimberly J. Popovits</i>	12,546	144,071	8,398	135,673	2,799	—
<i>Barry D. Quart</i>	12,546 ⁽⁸⁾	162,831	8,398	154,433	2,799	—
Total	33,617,871	4,265,619	717,895	3,547,724	180,544	194,111

(1) Consists of (a) 60,000 Class A Shares held by the Patel Family Irrevocable Trust of 2025 (the "Patel Family Trust"), for which Mr. Patel acts as the trustee, (b) 109,795 Class A Shares held by the Marina 2016 Irrevocable Trust u/d/t June 23, 2016 (the "Marina Trust"), for which Mr. Patel acts as the trustee, (c) 51,794 Class A Shares held by held by The Anglia 2013 Revocable Trust, u/d/t August 15, 2013 (the "Anglia Trust"), for which Mr. Patel acts as the trustee and (d) 1,526,160 Class B ordinary shares ("Class B Shares") held by the Anglia Trust.

(2) In the year ended 31 December 2025, Mr. Patel exercised and sold a total of 357,555 share options, which were originally granted on dates ranging from December 2015 to June 2017 with exercise prices ranging from \$1.59 to \$3.80. On 7 May 2025, Mr. Patel sold 1,965 shares for a per share average weighted price of \$27.00. On 8 May 2025, Mr. Patel sold 101 shares for a per share average weighted price of \$27.00. On 9 May 2025, Mr. Patel sold 6,029 shares for a per share average weighted price of \$27.05. On 13 May 2025, Mr. Patel sold 2,872 shares for a per share average weighted price of \$27.03. On 20 May 2025, Mr. Patel sold 2,349 shares for a per share average

**Kiniksa Pharmaceuticals International, plc
Directors' Remuneration Report
For the year ended 31 December 2025**

weighted price of \$27.02. On 23 May 2025, Mr. Patel sold 4,837 shares for a per share average weighted price of \$27.00. On 27 May 2025, Mr. Patel sold 19,317 shares for a per share average weighted price of \$27.01. On 28 May 2025, Mr. Patel sold 62,116 shares for a per share average weighted price of \$27.33. On 20 October 2025, Mr. Patel sold 98,934 shares for a per share average weighted price of \$38.81 and 22,314 shares for a per share average weighted price of \$39.32. On 21 October 2025, Mr. Patel sold 39,331 shares for a per share average weighted price of \$38.77. On 22 October 2025, Mr. Patel sold 97,390 shares for a per share average weighted price of \$38.83.

- (3) Reflects PSU vesting at maximum payout. Depending on the outcome of the approved performance metrics for the PSUs, the number of Class A Shares that may ultimately be issued ranges from a minimum issuance of 0% to a maximum issuance of 200% for annually granted PSUs and 0% to 100% for PSUs granted pursuant to the KPL-387 LTIP.
- (4) Consists of (a) 2,700,597 Class A Shares held by Baker Brothers Life Sciences, L.P. ("**BBLs**"), (b) 98,980 Class A Shares held by 667, L.P. ("**667**") and with BBLs, the "**Baker Funds**", (c) 11,638,314 Class A1 ordinary shares ("**Class A1 Shares**") held by BBLs, (d) 1,143,650 Class A1 Shares held by 667, (e) 14,658,102 Class B1 ordinary shares ("**Class B1 Shares**") held by BBLs, (f) 1,399,516 Class B1 Shares held by 667, (g) 27,386 Class A Shares held by Felix J. Baker, (h) 12,546 Class A Shares held by Stephen R. Biggar, (i) 1,577 Class A Shares held by M. Cantey Boyd, (j) 14,840 Class A Shares held by Julian C. Baker and (k) 7,320 Class A Shares held by FBB3 LLC ("**FBB3**").
- (5) Baker Bros. Advisors LP (the "**Advisor**") is the investment advisor to the Baker Funds and has the sole voting and investment power with respect to the securities held by the Baker Funds and thus may be deemed to beneficially own such securities. Baker Bros. Advisors (GP) LLC (the "**Advisor GP**") is the sole general partner of the Advisor and thus may be deemed to beneficially own the securities held by the Baker Funds. The managing members of the Advisor GP are Julian C. Baker and Felix J. Baker, who may be deemed to beneficially own the securities held by the Baker Funds. Julian C. Baker, Felix J. Baker, the Advisor and the Advisor GP disclaim beneficial ownership of all shares held by the Baker Funds, except to the extent of their indirect pecuniary interest therein. The policy of the Baker Funds and the Advisor does not permit managing members of the Advisor GP or full-time employees of the Advisor to receive compensation for serving as Directors of Kiniksa, and the Baker Funds are instead entitled to the pecuniary interest in any compensatory interest received for their service. Felix J. Baker and Stephen R. Biggar have no direct voting or dispositive power and no pecuniary interest in the share options or the RSUs. Julian C. Baker and Felix J. Baker are the sole managers of FBB3 and by policy they do not transact in or vote our securities held by FBB3. The Advisor, the Advisor GP, Felix J. Baker and Julian C. Baker may be deemed to be the beneficial owners of our securities held by the Baker Funds, and may be deemed to have the power to vote, or direct the vote of, and the power to dispose, or direct the disposition of, such securities. Felix J. Baker and Stephen R. Biggar disclaim beneficial ownership of such securities except to the extent of any pecuniary interest therein. The foregoing information is based on a Schedule 13D/A filed on 10 October 2024 and information known to us.

**Kiniksa Pharmaceuticals International, plc
Directors' Remuneration Report
For the year ended 31 December 2025**

- (6) Includes 71,967 Class A Shares held by Mossrock Capital, LLC (“**Mossrock**”). Mr. Malley is the president of Mossrock and may be deemed to beneficially own the shares owned by Mossrock.
- (7) In the year ended 31 December 2025, Mr. Malley exercised and sold a total of 177,769 share options, which were originally granted on dates ranging from December 2016 to June 2023 and with exercise prices ranging from \$1.86 to \$15.47. On 12 August 2025, Mr. Malley sold 49,407 shares for a per share average weighted price of \$32.40. On 13 August 2025, Mr. Malley sold 50,129 shares for a per share average weighted price of \$33.32. On 14 August 2025, Mr. Malley sold 78,233 shares for a per share average weighted price of \$33.09.
- (8) In the year ended 31 December 2025, Dr. Quart exercised and sold a total of 47,577 share options, which were originally granted on dates ranging from June 2017 to March 2018 and with exercise prices ranging from \$3.80 to \$10.36. On 9 June 2025, Dr. Quart sold 6,900 shares for a per share average weighted price of \$30.26. On 10 June 2025, Dr. Quart sold 8,212 shares for a per share average weighted price of \$30.36. On 11 June 2025, Dr. Quart sold 12,336 shares for a per share average weighted price of \$30.39. On 15 December 2025, Dr. Quart sold 20,129 shares for a per share average weighted price of \$41.51.

The following summarizes the details of the share options, RSUs and PSUs granted in the year ended 31 December 2025.

Name	Grant Date	Option Exercise Price per Share (\$) ⁽¹⁾	Face Value of Award ⁽²⁾	Award Type	Granted in 2025	Exercised in 2025	Vesting Terms
Executive Directors							
<i>Sanj K. Patel</i>	2025-04-01	\$ 21.77	\$ 2,996,379	Option	137,638	—	(3)
	2024-09-01	\$ 33.49	\$ 4,609,497	Option	137,638	—	(3)
	2025-04-01	N/A ⁽⁴⁾	\$ 749,650	RSU	34,435	—	(5)
	2024-09-01	N/A ⁽⁶⁾	\$ 1,153,228	RSU	34,435	—	(5)
	2025-04-01	N/A ⁽⁴⁾	\$ 1,499,278	PSU	68,869	—	(7)
	2025-05-01	N/A ⁽⁸⁾	\$ 221,559	PSU	7,987	—	(9)
	2025-05-01	N/A ⁽⁹⁾	\$ 232,628	PSU	8,386	—	(9)
	2025-05-01	\$ 27.74	\$ 358,123	PSO	12,910	—	(9)
	2025-05-01	\$ 27.74	\$ 369,719	PSO	13,328	—	(9)
Non-Executive Directors							
<i>Felix J. Baker</i>	2025-06-03	\$ 29.11	\$ 488,990	Option	16,798	—	(10)
	2025-06-03	N/A ⁽¹¹⁾	\$ 81,479	RSU	2,799	—	(12)
<i>Stephen R. Biggar</i>	2025-06-03	\$ 29.11	\$ 488,990	Option	16,798	—	(10)
	2025-06-03	N/A ⁽¹¹⁾	\$ 81,479	RSU	2,799	—	(12)
<i>M. Cantey Boyd</i>	2025-06-03	\$ 29.11	\$ 488,990	Option	16,798	—	(10)
	2025-06-03	N/A ⁽¹¹⁾	\$ 81,479	RSU	2,799	—	(12)
<i>G. Bradley Cole</i>	2025-06-03	\$ 29.11	\$ 488,990	Option	16,798	—	(10)
	2025-06-03	N/A ⁽¹¹⁾	\$ 81,479	RSU	2,799	—	(12)
<i>Richard S. Levy</i>	2025-06-03	\$ 29.11	\$ 488,990	Option	16,798	—	(10)
	2025-06-03	N/A ⁽¹¹⁾	\$ 81,479	RSU	2,799	—	(12)

**Kiniksa Pharmaceuticals International, plc
Directors' Remuneration Report
For the year ended 31 December 2025**

<i>Thomas R. Malley</i>	2025-07-01	N/A ⁽¹³⁾	\$	29.11	N/A ⁽¹³⁾	\$	29.11	29,991	RSU	1,101	—	(14)
	2025-06-03			29.11			29.11	488,990	Option	16,798	—	(10)
	2025-06-03			N/A ⁽¹¹⁾			N/A ⁽¹¹⁾	81,479	RSU	2,799	—	(12)
<i>Tracey L. McCain</i>	2025-06-03			29.11			29.11	488,990	Option	16,798	—	(10)
	2025-06-03			N/A ⁽¹¹⁾			N/A ⁽¹¹⁾	81,479	RSU	2,799	—	(12)
<i>Kimberly J. Popovits</i>	2025-06-03			29.11			29.11	488,990	Option	16,798	—	(10)
	2025-06-03			N/A ⁽¹¹⁾			N/A ⁽¹¹⁾	81,479	RSU	2,799	—	(12)
<i>Barry D. Quart</i>	2025-06-03			29.11			29.11	488,990	Option	16,798	—	(10)
	2025-06-03			N/A ⁽¹¹⁾			N/A ⁽¹¹⁾	81,479	RSU	2,799	—	(12)

- (1) The exercise price of a share option corresponds to the closing price of our Class A Shares on the date of grant.
- (2) Face value of award (a) for share options, reflects the option exercise price multiplied by the number of Class A Shares underlying the option, (b) for RSUs, reflects the closing price of our Class A Shares on the date of grant multiplied by the number of Class A Shares underlying the RSUs and (c) for PSUs, reflects the closing price of our Class A Shares on the date of grant multiplied by the number of Class A Shares underlying the PSUs, assuming target payout.
- (3) 25% of the option vests on the first anniversary of the date of grant, generally subject to continued service to Kiniksa. Thereafter the remainder of the option vests in 36 monthly installments, generally subject to continued service to Kiniksa.
- (4) The closing price of our Class A Shares on the date of grant was \$21.77.
- (5) 25% of the RSUs vest on each of the four anniversaries following the date of grant, generally subject to continued service to Kiniksa.
- (6) The closing price of our Class A Shares on the date of grant was \$33.49.
- (7) PSUs represent a contingent right to receive a number of Class A Shares based upon the achievement of certain pre-established performance criteria, as certified by the Committee. PSUs vest after three years. Depending on the outcome of the approved performance metrics for the PSUs, the number of Class A Shares that may ultimately be issued ranges from a minimum issuance of 0% to a maximum issuance of 200% of the PSUs. Specifics of such performance metrics, including achievement thresholds, is considered by the Committee to be prejudicial and/or commercially sensitive information. The Committee has determined that due to such prejudicial and/or commercial sensitivity, it will not disclose such information now or ever.
- (8) The closing price of our Class A Shares on the date of grant was \$27.74.

**Kiniksa Pharmaceuticals International, plc
Directors' Remuneration Report
For the year ended 31 December 2025**

- (9) PSUs represent a contingent right to receive a number of Class A Shares based upon the achievement of certain pre-established performance criteria, as set forth in the KPL-387 LTIP. The PSUs vest, if at all, after achievement of such performance criteria. Depending on the date of achievement, the number of Class A Shares that may ultimately be issued ranges from a minimum issuance of 0% to a maximum issuance of 100% of the PSUs. Specifics of such performance criteria, including target vesting achievement dates, is considered by the Committee to be prejudicial and/or commercially sensitive information. The Committee has determined that due to such prejudicial and/or commercial sensitivity, it will not disclose such information now or ever.
- (10) The option vests in 12 monthly installments following the date of grant, generally subject to continued service to Kiniksa.
- (11) The closing price of our Class A Shares on the date of grant was \$29.11.
- (12) The RSUs vest in their entirety on the sooner of the anniversary of the date of grant or the date of the 2027 AGM, generally subject to continued service to Kiniksa.
- (13) The closing price of our Class A Shares on the date of grant was \$27.24.
- (14) Granted in connection with Dr. Levy's performance of certain specified consulting services as described elsewhere in this Directors' Remuneration Report. The RSUs vested in their entirety on the date of grant.

The following table sets forth information with respect to the share ownership by our Directors of our Class A Shares, Class A1 Shares, Class B Shares and Class B1 Shares, as of 31 December 2025. Applicable percentage ownership is based on 45,659,424 Class A Shares issued and outstanding, 1,795,158 Class B Shares issued and outstanding, 12,781,964 Class A1 Shares issued and outstanding, and 16,057,618 Class B1 Shares issued and outstanding, each as of 31 December 2025. Each of the shareholders listed has sole voting and investment power with respect to the shares beneficially owned by the shareholder unless noted otherwise, subject to community property laws where applicable.

Name	Class A Shares	Class A Shares (%)	Class A1 Shares	Class A1 Shares (%)	Class B Shares	Class B Shares (%)	Class B1 Shares	Class B1 Shares (%)	Total Shares	Total Shares As Converted (%)
Executive										
Directors										
Sanj K. Patel	221,589 ⁽¹⁾	0.49 %	—	—	1,526,160 ⁽²⁾	85.02 %	—	—	1,747,749	2.29 %

**Kiniksa Pharmaceuticals International, plc
Directors' Remuneration Report
For the year ended 31 December 2025**

Non-Executive Directors	⁽³⁾⁽⁴⁾	%	⁽³⁾⁽⁴⁾	%	⁽³⁾⁽⁴⁾	%
Felix J. Baker	2,863,246	6.27	12,781,964	100	16,057,618	100
Stephen R. Biggar M.	12,546	0.03	—	—	—	—
Cantey Boyd G.	1,577	0.00	—	—	—	—
Bradley Cole	12,546	0.03	—	—	—	—
Rich Levy Thomas	18,474	0.04	—	—	—	—
R. Malley	84,513 ⁽⁵⁾	0.19	—	—	—	—
Tracey L. McCain	12,546	0.03	—	—	—	—
Kimberly J. Popovits	12,546	0.03	—	—	—	—
Barry D. Quart	12,546	0.03	—	—	—	—
Total	3,252,129	7.12	12,781,964	100	1,526,160	85.02
						16,057,618
						100
						33,617,871
						44.06

(1) Consists of (a) 60,000 Class A Shares held by the Patel Family Trust, (b) 51,794 Class A Shares held by the Anglia Trust and (c) 109,795 Class A Shares held by the Marina Trust.

(2) Consists of 1,526,160 Class B Shares held by the Anglia Trust.


**Kiniksa Pharmaceuticals International, plc
Directors' Remuneration Report
For the year ended 31 December 2025**

- (3) Consists of (a) 2,700,597 Class A Shares held by BBLs, (b) 98,980 Class A Shares held by 667, (c) 11,638,314 Class A1 Shares held by BBLs, (d) 1,143,650 Class A1 Shares held by 667, (e) 14,658,102 Class B1 Shares held by BBLs, (f) 1,399,516 Class B1 Shares held by 667, (g) 27,386 Class A Shares held by Felix J. Baker, (h) 12,546 Class A Shares issued to Stephen R. Biggar pursuant to the vesting of certain RSUs awarded in connection with his service as a member of our Board of Directors, (i) 14,840 Class A Shares held by Julian C. Baker, (j) 1,577 Class A Shares issued to M. Cantey Boyd pursuant to the vesting of certain RSUs awarded in connection with her service as a member of our Board of Directors and (k) 7,320 Class A Shares held by FBB3.
- (4) The Advisor is the investment advisor to the Baker Funds and has the sole voting and investment power with respect to the securities held by the Baker Funds and thus may be deemed to beneficially own such securities. Advisor GP is the sole general partner of the Advisor and thus may be deemed to beneficially own the securities held by the Baker Funds. The managing members of the Advisor GP are Julian C. Baker and Felix J. Baker, who may be deemed to beneficially own the securities held by the Baker Funds. Julian C. Baker, Felix J. Baker, the Advisor and the Advisor GP disclaim beneficial ownership of all shares held by the Baker Funds, except to the extent of their indirect pecuniary interest therein. The policy of the Baker Funds and the Advisor does not permit managing members of the Advisor GP or full-time employees of the Advisor to receive compensation for serving as Directors of Kiniksa, and the Baker Funds are instead entitled to the pecuniary interest in any compensation received for their service. Felix J. Baker and Stephen R. Biggar have no direct voting or dispositive power and no pecuniary interest in the share options or the RSUs. Julian C. Baker and Felix J. Baker are the sole managers of FBB3 and by policy they do not transact in or vote our securities held by FBB3. The Advisor, the Advisor GP, Felix J. Baker and Julian C. Baker may be deemed to be the beneficial owners of our securities held by the Baker Funds, and may be deemed to have the power to vote, or direct the vote of, and the power to dispose, or direct the disposition of, such securities. Felix J. Baker, Stephen R. Biggar and M. Cantey Boyd disclaim beneficial ownership of such securities except to the extent of any pecuniary interest therein. The foregoing information is based on a Schedule 13D/A filed on October 10, 2024 and information known to us.
- (5) Consists of (a) 12,546 Class A Shares held by Mr. Malley and (b) 71,967 Class A Shares held by Mossrock. Mr. Malley is the president of Mossrock and may be deemed to beneficially own the shares owned by Mossrock.

**Kiniksa Pharmaceuticals International, plc
 Directors' Remuneration Report
 For the year ended 31 December 2025**

Total Shareholder Return for Kiniksa International's Class A Shares

The following graph shows a comparison of the total cumulative returns of an investment of \$100 in cash from 25 May 2018 (the first day that the Company's Class A Shares became publicly traded) through 31 December 2025 in (i) our Class A Shares, (ii) the Nasdaq Composite Index and (iii) the Nasdaq Biotechnology Index. These comparators were chosen as they reflect (a) with respect to the Nasdaq Composite Index, the relative growth of the market as a whole and (b) with respect to the Nasdaq Biotechnology Index, the relative growth of the Company's industry. The comparisons in the graph are not intended to forecast or be indicative of the possible future performance of our common shares. The graph assumes that all dividends have been reinvested (to date, we have not declared any dividends).



**Kiniksa Pharmaceuticals International, plc
Directors' Remuneration Report
For the year ended 31 December 2025**

Chief Executive Officer Total Remuneration History

The following table presents data showing the percentage change from 2024 to 2025 with respect to the base salaries, benefits and annual cash bonuses of our Executive Director and our employees on a cumulative basis.

	Year Ended 31 December	
	2024	2025
Sanj K. Patel		
Chief Executive Officer and Executive Director		
<i>Single Total Figure of Remuneration</i>	(1) \$ 2,345,261	\$ 2,794,087
<i>Annual Bonus as a Percentage of Maximum Bonus Eligibility</i>	(2) 61.88 %(3)	62.50 %(4)
<i>Long-Term Incentive Plan Compensation as a Percentage of Maximum Eligibility</i>	(6)(7) –	–

- (1) Reflects the value in the column labeled "Total Remuneration" in the Single Total Figure of Remuneration of each Director table above.
- (2) While there is not a defined maximum amount of cash bonus that can be approved by the Committee, it exercises discretion to approve bonus payouts reasonable in the context of individual and overall company performance and historically above-target payouts have not exceeded 200% of target bonus. For purposes of this table only, the historical 200% cap is being used in place of a formal maximum.
- (3) Reflects a bonus payout of 80% of the Executive Director's salary. The Executive Director's bonus target for the given year was 65%
- (4) Reflects a bonus payout of 81% of the Executive Director's salary. The Executive Director's bonus target for the given year was 65%
- (5) Reflects a bonus payout of 136% of the Executive Director's salary. The Executive Director's bonus target for the given year was 75%
- (6) The Directors receive market value share options as part of their remuneration with an exercise price equivalent to the closing price of our Class A Shares on the date of grant. These options are not subject to performance conditions. The remuneration value of such awards in the year of award is not included because there is no intrinsic value at the applicable date of grant. Refer to "Statement of Directors' Shareholder and Share Interests" above. Granted PSUs are disregarded from the value of long-term equity awards in the year of grant and will instead be reflected in the value of long-term equity award remuneration in the year in which the applicable performance period ends.
- (7) While there is not a defined maximum amount of equity awards that can be approved by the Committee, it exercises discretion to approve awards reasonable in the context of individual and overall company performance and historically has not granted awards with a cumulative fair market value in excess of 800% of a Director's base salary. Because no remuneration was reported in the Single Total Figure of

**Kiniksa Pharmaceuticals International, plc
Directors' Remuneration Report
For the year ended 31 December 2025**

Remuneration of each Director table related to long-term incentive equity remuneration for the year ended 31 December 2025, these columns reflect a percentage of 0%.

**Kiniksa Pharmaceuticals International, plc
Directors' Remuneration Report
For the year ended 31 December 2025**

Percentage Change in Remuneration of our Directors and Employees

2024 was the first year for which the Company has prepared a Remuneration Report. We have presented data showing the percentage change from 2023 to 2025 with respect to base salaries, benefits and annual cash bonuses for each of our Directors and our employees as a whole. We expect to report the percentage change in remuneration for our Directors for 2023 onwards. The following tables reflect the year-over-year increases in each of (a) base salaries (b) benefits and (c) annual bonuses for each of our Directors and for all employees (other than the Executive Director) as a whole.

	Year Ended 31 December		Increase/ (Decrease) %	Year Ended 31 December		Increase/ (Decrease) %	Year Ended 31 December		Increase/ (Decrease) %		
	2023	2024		2023	2024		2023	2024			
	\$	\$		\$	\$		\$	\$			
Executive Directors											
Sanj K. Patel	864,780	899,371	4.00 %	32,237	32,417	180	0.56 %	695,663 ⁽²⁾	730,739 ⁽³⁾	35,076	5.04 %
Non-Executive Directors											
Felix J. Baker	94,700	91,350	(3.50)%	—	—	—	—	—	—	—	—
Stephen R. Biggar	55,600	55,600	0.00 %	—	—	—	—	—	—	—	—
M. Cantley Boyd	—	11,575	n/a	—	—	—	—	—	—	—	—
G. Bradley Cole	49,000	49,000	0.00 %	—	—	—	—	—	—	—	—
Richard S. Levy	53,400	53,400	0.00 %	—	—	—	—	—	—	—	—
Thomas R. Malley	64,000	65,575	2.46 %	—	—	—	—	—	—	—	—
Tracey L. McCain	49,000	49,000	0.00 %	—	—	—	—	—	—	—	—
Kimberly J. Popovits	46,300	49,650	7.24 %	—	—	—	—	—	—	—	—
Barry D. Quart	56,193	63,175	12.43 %	—	—	—	—	—	—	—	—
Employees⁽⁴⁾	51,137	64,475	26.08 %	4,042	5,255	1,213	30.01 %	10,151	11,234	1,083	10.67 %

(1) None of the Non-Executive Directors were eligible to receive benefits or cash annual bonuses.

(2) Reflects a bonus payout of 80% of the Executive Director's salary. The Executive Director's bonus target for the given year was 65%

(3) Reflects a bonus payout of 81% of the Executive Director's salary. The Executive Director's bonus target for the given year was 65%

(4) Employee data in thousands. Reflects total Company expenditures on salaries, annual cash bonuses and benefits on all employees other than the Executive Director.

**Kiniksa Pharmaceuticals International, plc
Directors' Remuneration Report
For the year ended 31 December 2025**

	Base Salary		Benefits ⁽¹⁾		Annual Bonus ⁽¹⁾	
	Year Ended 31 December	Increase/ (Decrease)	Year Ended 31 December	Increase/ (Decrease)	Year Ended 31 December	Increase/ (Decrease)
	2025	\$ %	2025	\$ %	2025	\$ %
Executive Directors						
Sanj K. Patel	899,371	43,758 4.87 %	32,417	255 0.79 %	730,739 ⁽²⁾	553,326 75.72 %
Non-Executive Directors						
Felix J. Baker	91,350	2,649 2.90 %	—	—	—	—
Stephen R. Biggar	55,600	13,399 24.10 %	—	—	—	—
M. Cantey Boyd	11,575	47,425 409.72 %	—	—	—	—
G. Bradley Cole	49,000	59,999 22.45 %	—	—	—	—
Richard S. Levy	53,400	69,998 31.08 %	—	—	—	—
Thomas R. Malley	65,575	74,999 14.37 %	—	—	—	—
Tracey L. McCain	49,000	59,999 22.45 %	—	—	—	—
Kimberly J. Popovits	49,650	20,349 40.98 %	—	—	—	—
Barry D. Quart	63,175	77,999 23.46 %	—	—	—	—
Employees⁽⁴⁾	64,475	9,304 14.43 %	5,255	1,084 26.08 %	11,234	2,113 18.81 %

(1) None of the Non-Executive Directors were eligible to receive benefits or cash annual bonuses.

(2) Reflects a bonus payout of 81% of the Executive Director's salary. The Executive Director's bonus target for the given year was 65%

(3) Reflects a bonus payout of 136% of the Executive Director's salary. The Executive Director's bonus target for the given year was 75%

(4) Employee data in thousands. Reflects total Company expenditures on salaries, annual cash bonuses and benefits on all employees other than the Executive Director.

Kiniksa Pharmaceuticals International, plc
Directors' Remuneration Report
For the year ended 31 December 2025

Relative Importance of Spend on Pay

The table below illustrates the Group's expenditure on pay for the year ending 31 December 2025. The comparator chosen to reflect the relative importance of the Group's spend on pay is the Group's research and development expenses due to the nature and stage of the Company's business as a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need. For more information on research and development expense, please see "Part II – Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Form 10-K.

Employee pay expenditure reflects employee-related expenses, including salaries and benefits, travel expenses, and share-based compensation expenses for the Group's employees. Dividend distribution comparators are not included as the Company has no history of such transactions and has no plans to pay dividends in the future.

	Year ending 31 December		Increase/ (decrease)	
	2024	2025	(\$)	(%)
Research and Development Expenses (\$) (in thousands)	111,623	96,853	(14,770)	(13.23)%
Total Group employee pay expenditure (\$) (in thousands)	106,747 ⁽¹⁾	120,310 ⁽¹⁾	13,563	12.71 %

(1) Includes salaries, the value of share awards granted in the year, annual bonuses paid for such year, benefits and Company contributions to retirement plans.

Structure and Role of Committee and approach to Remuneration Matters

The Committee is comprised of Kimberly Popovits, who chairs the Committee, M. Cantey Boyd and Barry D. Quart. The Committee maintains a charter in compliance with Nasdaq's rules and requirements. The members of the Committee are annually evaluated and determined by the Board as being independent under Nasdaq rules.

The Board maintains corporate governance guidelines that set forth a flexible framework with which the Board and its committees exercise responsibility. Such guidelines are reviewed annually by the Board's Nominating and Corporate Governance Committee, which proposes updates as necessary.

The Committee approaches remuneration as a means to attract and retain talent and incentivize long-term growth in line with the interests of the Company's stakeholders. For the Executive Director, the Committee views these goals as most effectively achieved through an emphasis on variable over fixed remuneration, granting long-term incentive equity awards and, in the year ended 31 December 2024, introducing PSUs to the Executive Director's remuneration package. The Committee also reserves the ability to deploy flexible grants and payments, as needed, to incentive and retain talent or to incentivize the Company's employees to achieve significant and challenging goals, such as through the KPL-387 LTIP.

When applying the Policy to the Executive Director, the Committee seeks to comply with applicable rules and regulations as far as practicable, having regard to the size, nature and business requirements of the Company. Operation of the Policy that differs from UK norms reflect differences in United States market practices when compared to those in the UK, and the need to balance governance obligations against the importance of offering competitive remuneration packages in the markets in which we compete and operate.

Relevant documentation, including the Committee's charter, can be found at: <https://investors.kiniksa.com/corporate-governance/documents-charters>.

**Kiniksa Pharmaceuticals International, plc
Directors' Remuneration Report
For the year ended 31 December 2025**

External Advice

The Committee has the authority to retain or obtain the advice of compensation consultants, legal counsel and other advisors to assist in carrying out its responsibilities. During the year ended 31 December 2025, the Committee retained an independent remuneration consulting firm, Compensia, Inc. ("**Compensia**"), to assess and, as applicable, make recommendations with respect to the amount and types of remuneration to provide to our Directors, among related matters. Compensia reported directly to the Committee. The Committee reviewed compensation assessments provided by Compensia comparing our Directors' compensation to that of compensation peer group within our industry, and met with Compensia to discuss such assessments. The Committee retains ultimate discretion to review and approve the Company's compensation peer group by which the remuneration of the Directors is evaluated. The Committee considered the advisor independence factors required under SEC and Nasdaq rules as they relate to Compensia, and did not find any conflicts of interest concerns in 2025. During the year ended 31 December 2025, fees of \$222,512 were paid to Compensia, which were incurred on a time and expenses basis. No other services were provided by Compensia to the Company in the year ended 31 December 2025.

The Committee selected Compensia for its expertise, history with the Company and quality of service. Each year the Committee considers the advisor independence factors required under SEC and Nasdaq rules as they relate to Compensia. The Committee did not find any conflicts of interest concerns in the year ended 31 December 2025.

Proposed Application of the Policy for the Year Ending 31 December 2026

Executive Director Remuneration

Fixed Elements of Cash Remuneration. Effective 1 January 2026, the annual base salary of Sanj K. Patel in his role as Chief Executive Officer and Executive Director is \$995,000.

Variable Elements of Cash Remuneration. The target bonus for Mr. Patel in the year ending 31 December 2026 is 80% of base salary. The Committee reviewed 2026 corporate goals in January 2026, and Mr. Patel's annual bonus for the year ending 31 December 2026 will be determined, in part, based on the Company's achievement of such goals. The details of such goals are considered prejudicial and/or commercially sensitive. To the extent that the objectives do not comprise commercially sensitive information, the Company expects to disclose such goals in next year's Remuneration Report, subject to redaction of commercially sensitive/prejudicial information.

Long-Term Equity Incentive Awards. In March 2026, the Committee approved grants of (a) 120,150 share options, (b) 30,050 RSUs and (c) 60,100 PSUs to Mr. Patel, and expects to make additional grants of share options and RSUs to Mr. Patel in September of 2026 in accordance with its biannual equity award granting practice. Such awards are designed to align Mr. Patel's interests with those of our shareholders. The Company will report certain details of the grants in its filings with the SEC and in next year's Remuneration Report. Specifics of the PSU's performance metrics, including achievement thresholds, is considered by the Committee to be prejudicial and/or commercially sensitive information. The Committee has determined that due to such prejudicial and/or commercial sensitivity, it will not disclose such information now or ever.

Benefits. Mr. Patel will be eligible for the same benefits (e.g., health insurance, life insurance, disability insurance, and 401(k) matching contributions) as he received in the year ended 31 December 2025.

**Kiniksa Pharmaceuticals International, plc
Directors' Remuneration Report
For the year ended 31 December 2025**

For a chart showing the expected remuneration under base case, target and expected maximum scenarios, see above under "Application of the Remuneration Policy to Executive Director Remuneration for the Year Ending 31 December 2026".

Non-Executive Director Fees

Effective 2 February 2026 with respect to Subsequent Awards and 17 March 2026 with respect to Initial Awards, the Company increased equity payments eligible to be earned by its Non-Executive Directors as set forth in the following table. Cash retainers were not increased.

Retainers for the Chair/Lead Independent Director as well as committee chair/member retainers are in addition to the retainer for serving on the Board. The increases were driven by a need to provide market-competitive equity compensation to our Non-Executive Directors.

Board Position	Cash Retainer in the Year Ending 31 December	
	2025	2026
<i>Director</i>	\$ 50,000	\$ 50,000
<i>Chair or Lead Independent Director</i>	\$ 30,000	\$ 30,000
<i>Audit Committee Chair</i>	\$ 20,000	\$ 20,000
<i>Compensation Committee Chair</i>	\$ 20,000	\$ 20,000
<i>Nominating and Corporate Governance Committee Chair</i>	\$ 10,000	\$ 10,000
<i>Science and Research Committee Chair</i>	\$ 20,000	\$ 20,000
<i>Audit Committee Member</i>	\$ 10,000	\$ 10,000
<i>Compensation Committee Member</i>	\$ 9,000	\$ 9,000
<i>Nominating and Corporate Governance Committee Member</i>	\$ 5,000	\$ 5,000
<i>Science and Research Committee Member</i>	\$ 9,000	\$ 9,000

	Equity Award in Year Ending 31 December	
	2025 ⁽¹⁾	2026 ⁽²⁾
Initial Award	\$ 600,000	\$ 700,000
Subsequent Award	\$ 340,000	\$ 400,000

(1) Award reflects such value, divided by the Black-Scholes value of a Class A Share, rounded down to the nearest whole share. Such grants shall not exceed 80,000 Class A Shares with respect to Initial Awards and 40,000 Class A Shares with respect to Subsequent Awards.

(2) Award reflects such value, divided by the Black-Scholes value of a Class A Share, rounded down to the nearest whole share. Such grants shall not exceed 93,300 Class A Shares with respect to Initial Awards and 53,600 Class A Shares with respect to Subsequent Awards.

Board Composition

In accordance with the Company's Articles of Association, Non-Executive Directors are elected by the Company's shareholders for a three-year term of office, and successors to the class of Directors whose term expires at a given AGM are elected for a subsequent three-year term. At each AGM, the Directors (or applicable successors) in the class whose term is expiring will stand for re-election (or election) pursuant to an ordinary resolution. At the 2026 AGM, Stephen R. Biggar, G. Bradley Cole and Barry D. Quart will be eligible for re-election.

**Kiniksa Pharmaceuticals International, plc
Directors' Remuneration Report
For the year ended 31 December 2025**

We currently have ten Directors on our Board, including three Class I Directors consisting of Sanj K. Patel, Thomas R. Malley, and Richard S. Levy; three Class II Directors consisting of Stephen R. Biggar, G. Bradley Cole, and Barry D. Quart; and four Class III Directors consisting of Felix J. Baker, M. Cantey Boyd, Tracey L. McCain, and Kimberly J. Popovits.

The current composition of the Board and its committees, including which Directors serve as committee chairs, is as follows:

<u>Name</u>	<u>Audit</u>	<u>Compensation</u>	<u>Nominating and Corporate Governance</u>	<u>Science and Research</u>
Executive Directors				
<i>Sanj K. Patel</i>				
Non-Executive Directors				
<i>Felix J. Baker</i>				
			X	X
<i>Stephen R. Biggar</i>				
			Chair	X
<i>M. Cantey Boyd</i>				
		X		
<i>G. Bradley Cole</i>				
	X			
<i>Richard S. Levy</i>				
				Chair
<i>Thomas R. Malley</i>				
	Chair		X	
<i>Tracey L. McCain</i>				
	X			
<i>Kimberly J. Popovits</i>				
		Chair		
<i>Barry D. Quart</i>				
	X	X		X

Attendance

Attendance of the Committee's meetings in the year ended 31 December 2025 were as follows:

<u>Committee Member</u>	<u>Attendance</u>
<i>M. Cantey Boyd</i>	2 of 2
<i>Kimberly J. Popovits</i>	2 of 2
<i>Barry D. Quart</i>	2 of 2

Independent auditors' report to the members of Kiniksa Pharmaceuticals International, plc

Report on the audit of the financial statements

Opinion

In our opinion:

- Kiniksa Pharmaceuticals International, plc's group financial statements and company financial statements (the "financial statements") give a true and fair view of the state of the group's and of the company's affairs as at 31 December 2025 and of the group's profit and the group's cash flows for the year then ended;
- the group financial statements have been properly prepared in accordance with accounting principles generally accepted in the United States of America as applied in accordance with the provisions of the Companies Act 2006;
- the company financial statements have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards, including FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", and applicable law); and
- the financial statements have been prepared in accordance with the requirements of the Companies Act 2006.

We have audited the financial statements, included within the Annual report and financial statements (the "Annual Report"), which comprise:

- the Consolidated Balance Sheet as at 31 December 2025;
- the Company balance sheet as at 31 December 2025;
- the Consolidated Statement of Operations and Comprehensive Income (Loss) for the year then ended;
- the Consolidated Statement of Shareholders' Equity for the year then ended;
- the Company statement of changes in equity for the year then ended;
- the Consolidated Statement of Cash Flows for the year then ended; and
- the notes to the financial statements, comprising material accounting policy information and other explanatory information.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) ("ISAs (UK)") and applicable law. Our responsibilities under ISAs (UK) are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Independence

We remained independent of the group in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, which includes the FRC's Ethical Standard, as applicable to listed entities, and we have fulfilled our other ethical responsibilities in accordance with these requirements.

Our audit approach

Context

Kiniksa Pharmaceuticals International, plc is a public limited company incorporated under the laws of England and Wales, and is listed on the NASDAQ. As such, the group and company financial statements are subject to an audit in accordance with the requirements of the UK Companies Act 2006.

Overview

Audit scope

- In relation to the group, the group's headquarters are in the United Kingdom, however it maintains its head office finance team in Lexington, Massachusetts, USA. We identified seven legal entities, including the company, which when grouped represent one component, collectively and hereafter referred to as Kiniksa Pharmaceuticals International, plc ("Kiniksa plc"). This component, in our view, required a full scope audit based on its contribution to revenue and loss before tax. All work in relation to Kiniksa plc for the group audit was performed by our PwC US (overseas supporting firm) team in Boston, under our direction and supervision. The audit procedures over the incremental ISA (UK) procedures as required for the group audit, were performed by PwC UK.
- In relation to the company, the audit engagement comprised the audit of the company financial statements of Kiniksa Pharmaceuticals International, plc. the audit procedures over the company financial statements were performed by PwC UK.

Key audit matters

- Accrued research and development expense relating to clinical trials (group)
- Product Revenue, net (group)
- Valuation of investment in subsidiaries (parent)

Materiality

- Overall group materiality: \$4.4 million (PY: \$3.1 million) based on 5% of income (loss) before income taxes from continuing operations (PY: 0.75% of total revenue).
- Overall company materiality: \$14.8 million (PY: 13.5 million) based on 1% of total assets.
- Performance materiality: \$3.3 million (PY: \$2.3 million) (group) and \$11.1 million (PY: \$10.1 million) (company).

The scope of our audit

As part of designing our audit, we determined materiality and assessed the risks of material misstatement in the financial statements.

Key audit matters

Key audit matters are those matters that, in the auditors' professional judgement, were of most significance in the audit of the financial statements of the current period and include the most significant assessed risks of material

Kiniksa Pharmaceuticals International, plc

misstatement (whether or not due to fraud) identified by the auditors, including those which had the greatest effect on: the overall audit strategy; the allocation of resources in the audit; and directing the efforts of the engagement team. These matters, and any comments we make on the results of our procedures thereon, were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

This is not a complete list of all risks identified by our audit.

Product Revenue, net is a new key audit matter this year. Otherwise, the key audit matters below are consistent with last year.

Key audit matter	How our audit addressed the key audit matter
<p>Accrued research and development expense relating to clinical trials (group)</p> <p>As described in Notes 2 and 9 to the consolidated financial statements, the Company has entered into various research and development-related contracts with companies both inside and outside of the United States. When billing terms under these contracts do not coincide with the timing of when the work is performed, management is required to make estimates of outstanding obligations to those third parties as of the end of the reporting period. Total accrued research and development expenses related to these estimated research and development obligations were \$6.6 million as of December 31, 2025. Accrual estimates are based on a number of factors, including management’s assessment of progress towards completion of the research and development activities, invoicing to date under the contracts, communication from the research institution or other companies of any actual costs incurred during the period that have not yet been invoiced, and the costs included in the contracts. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. The principal considerations for our determination that performing procedures relating to accrued research and development costs is a critical audit matter are (i) the significant judgment by management when developing the estimate of the accrued research and development costs and (ii) a high degree of auditor judgment, subjectivity, and effort in performing procedures and evaluating audit evidence for the factors related to management’s assessment of progress towards completion of the research and development activities, invoicing to date under the contracts, and communication from the research institution or other companies of any actual costs incurred during the period that have not yet been invoiced.</p>	<p>Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to accrued research and development costs, including controls over the review of contracts, accumulating information on actual costs incurred during the period, and assessment of progress towards completion of the research and development activities. These procedures also included, among others:</p> <ul style="list-style-type: none"> (i) testing management’s process for developing the estimate of accrued research and development costs; (ii) evaluating the appropriateness of the methodology used by management to develop the estimate; (iii) evaluating the reasonableness of the factors related to management’s assessment of progress towards completion of the research and development activities, invoicing to date under the contracts, and communication from the research institution or other companies of any actual costs incurred during the period that have not yet been invoiced by testing, on a sample basis, specific tasks and the associated cost incurred for services the Company has not yet been invoiced for or otherwise notified of the actual cost at December 31, 2025, and (iv) testing the completeness and accuracy of underlying data used by management. <p>No material audit findings have been identified from our testing.</p>
<p>Product Revenue, net (group)</p> <p>As described in Notes 2 and 4 to the consolidated financial statements, the Company’s product is sold through a third party logistics provider that distributes primarily through a network of authorized specialty pharmacies and specialty distributors. The Company’s net revenue from such product sales is recognized at the transaction price when the specialty pharmacy or specialty distributors obtain control of the Company’s products, which occurs at a point in time, typically upon shipment of the product from the third party logistics provider. The Company’s net revenues represent total revenues adjusted for discounts and allowances, including estimated cash discounts, chargebacks, rebates,</p>	<p>Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to the recognition of product revenue, net. These procedures also included, among others:</p> <ul style="list-style-type: none"> (i) testing revenue recognized for a sample of revenue transactions by obtaining and inspecting source documents, such as invoices, customer purchase orders, shipping documents, and cash receipts; and

Kiniksa Pharmaceuticals International, plc

<p>returns, copay assistance, and specialty pharmacy and distributor fees. For the year ended December 31, 2025, the Company recognized \$677.6 million of product revenue, net. The principal consideration for our determination that performing procedures relating to product revenue, net, is a critical audit matter is a high degree of auditor effort in performing procedures related to the Company's recognition of product revenue, net.</p>	<p>(ii) testing a sample of discounts and allowances transactions related to chargebacks and rebates by obtaining and inspecting source documents, which included support for contractual arrangements, units sold, and rebate payments.</p> <p>No material audit findings have been identified from our testing.</p>
<p>Valuation of investment in subsidiaries (parent)</p> <p>In 2024 the group undertook a corporate restructuring transaction, which involved Kiniksa Pharmaceuticals International, plc ("Kiniksa plc") becoming the ultimate parent company of the group in a share-for-share exchange with the existing shareholders of Kiniksa Pharmaceuticals, Ltd. The transaction involved a number of interconnected legal steps which resulted in Kiniksa plc recognising investment in subsidiaries. During the year, Kiniksa plc made a further investment in one of its' subsidiaries, meaning that as at 31 December 2025 investments in subsidiaries are valued at \$1,450 million. Management elected to initially recognise the investment at its fair value derived from the market capitalisation of the group. The valuation of this investment is significant to the company balance sheet. As of 31 December 2025, the market capitalisation of Kiniksa plc has consistently remained above the net assets held by the parent company and therefore management's impairment assessment concluded that there is no impairment. We determined that a relatively high degree of resources and effort were required in performing procedures related to the valuation risk that the carrying value of the investment in subsidiary could be impaired. This is due to the judgement involved in the impairment indicator assessment of the material balances. Refer to note 4 to the company financial statements.</p>	<p>We evaluated the directors' assessment regarding whether an impairment trigger existed. We found that management's assessment of no impairment trigger arising was appropriate, as the fair value of the group, by reference to the market capitalisation, supported the investment balances. We have performed following procedures to address the key audit matter:</p> <p>(i) We have obtained management's impairment assessment and assessed its reasonableness; and</p> <p>(ii) We assessed that there is not an indicator of impairment as the market capitalisation of the Group is greater than the net assets of the parent company as of 31 December 2025.</p> <p>Based on above procedures we concur with management's conclusion that no impairment is required on investments in subsidiary companies.</p>

How we tailored the audit scope

We tailored the scope of our audit to ensure that we performed enough work to be able to give an opinion on the financial statements as a whole, taking into account the structure of the group and the company, the accounting processes and controls, and the industry in which they operate.

The group's accounting process is structured around a group finance function located in Boston, Massachusetts, who maintain accounting records, controls and financial oversight for the group. The financial reporting team and the quarterly closing of the legal entities is performed in this one location where the consolidated balances are managed and controlled centrally at the Group level and recorded into the respective component trial balances. As such, we scoped and performed the audit at the consolidated level using the Group performance materiality for all material FSLIs. All work in relation to Kiniksa plc for the group audit was performed by our PwC US (overseas supporting firm) colleagues in Boston, under our direction and supervision. Our oversight procedures included the issuance of formal written instructions to the supporting firm setting out the work to be performed, regular communication during the planning, execution and completion phases of their audit including calls through video conferencing, participation in key meetings and review of component auditor work papers including their approach and findings. In addition, members of the group audit team visited the supporting audit firm.

Kiniksa Pharmaceuticals International, plc

The company is a holding company which exists to hold an investment in subsidiaries that comprises the remainder of the group. We tailored the scope of our audit to ensure that we performed sufficient audit work to be able to give an opinion on the financial statements as a whole, taking into account the nature of the company, its accounting processes and controls, and its relationship with the group.

The impact of climate risk on our audit

As part of our audit we made enquiries of management to understand the extent of the potential impact of climate risk on the group and company financial statements, and we remained alert when performing our audit procedures for any indicators of the impact of climate risk. Our procedures did not identify any material impact as a result of climate risk on the group and company financial statements.

Materiality

The scope of our audit was influenced by our application of materiality. We set certain quantitative thresholds for materiality. These, together with qualitative considerations, helped us to determine the scope of our audit and the nature, timing and extent of our audit procedures on the individual financial statement line items and disclosures and in evaluating the effect of misstatements, both individually and in aggregate on the financial statements as a whole.

Based on our professional judgement, we determined materiality for the financial statements as a whole as follows:

	Financial statements - group	Financial statements - company
Overall materiality	\$4.4 million (PY: \$3.1 million).	\$14.8 million (PY: 13.5 million).
How we determined it	5% of income (loss) before income taxes from continuing operations (PY: 0.75% of total revenue)	1% of total assets
Rationale for benchmark applied	We consider income (loss) before income taxes from continuing operations to be the most appropriate benchmark to determine materiality for the group as it is profit-oriented.	We consider total assets to be the most appropriate benchmark to determine materiality for the company as it is the ultimate holding company of the group which predominantly holds a material investment in subsidiaries.

We use performance materiality to reduce to an appropriately low level the probability that the aggregate of uncorrected and undetected misstatements exceeds overall materiality. Specifically, we use performance materiality in determining the scope of our audit and the nature and extent of our testing of account balances, classes of transactions and disclosures, for example in determining sample sizes. Our performance materiality was 75% (PY: 75%) of overall materiality, amounting to \$3.3 million (PY: \$2.3 million) for the group financial statements and \$11.1 million (PY: \$10.1 million) for the company financial statements.

In determining the performance materiality, we considered a number of factors - the history of misstatements, risk assessment and aggregation risk and the effectiveness of controls - and concluded that an amount at the upper end of our normal range was appropriate.

Kiniksa Pharmaceuticals International, plc

We agreed with those charged with governance that we would report to them misstatements identified during our audit above \$0.2 million (group audit) (PY: \$0.2 million) and \$0.7 million (company audit) (PY: \$0.7 million) as well as misstatements below those amounts that, in our view, warranted reporting for qualitative reasons.

Conclusions relating to going concern

Our evaluation of the directors' assessment of the group's and the company's ability to continue to adopt the going concern basis of accounting included:

- Obtaining from management their assessment which supports the Board's conclusions with respect to going concern basis of preparation of the group financial statements. Note, the company's ability to continue as a going concern is linked to the going concern of the group
- Testing the mathematical integrity of the cash flow forecasts and the models which extend through to the end of 2028, and reconciled these to the Board approved budgets
- Identifying and assessing management's alternate severe but plausible downside scenarios, and considering whether the assumptions in the downside scenario were reasonable and appropriate
- Assessing the reliability of cash flow forecasts by comparing actual performance to forecasts, specifically performing lookback testing over the budgeted results of the prior year
- Assessing the completeness of the going concern disclosures

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the group's and the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

However, because not all future events or conditions can be predicted, this conclusion is not a guarantee as to the group's and the company's ability to continue as a going concern.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Reporting on other information

The other information comprises all of the information in the Annual Report other than the financial statements and our auditors' report thereon. The directors are responsible for the other information. Our opinion on the financial statements does not cover the other information and, accordingly, we do not express an audit opinion or, except to the extent otherwise explicitly stated in this report, any form of assurance thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated. If we identify an apparent material inconsistency or material misstatement, we are required to perform procedures to conclude whether there is a

Kiniksa Pharmaceuticals International, plc

material misstatement of the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report based on these responsibilities.

With respect to the Strategic report and Directors' Report, we also considered whether the disclosures required by the UK Companies Act 2006 have been included.

Based on our work undertaken in the course of the audit, the Companies Act 2006 requires us also to report certain opinions and matters as described below.

Strategic report and Directors' Report

In our opinion, based on the work undertaken in the course of the audit, the information given in the Strategic report and Directors' Report for the year ended 31 December 2025 is consistent with the financial statements and has been prepared in accordance with applicable legal requirements.

In light of the knowledge and understanding of the group and company and their environment obtained in the course of the audit, we did not identify any material misstatements in the Strategic report and Directors' Report.

Directors' Remuneration

In our opinion, the part of the Directors' Remuneration Report to be audited has been properly prepared in accordance with the Companies Act 2006.

Responsibilities for the financial statements and the audit

Responsibilities of the directors for the financial statements

As explained more fully in the Statement of directors' responsibilities, the directors are responsible for the preparation of the financial statements in accordance with the applicable framework and for being satisfied that they give a true and fair view. The directors are also responsible for such internal control as they determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the group's and the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the group or the company or to cease operations, or have no realistic alternative but to do so.

Auditors' responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Kiniksa Pharmaceuticals International, plc

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

Based on our understanding of the group and industry, we identified that the principal risks of non-compliance with laws and regulations related to Companies Act 2006 and applicable tax legislation, and we considered the extent to which non-compliance might have a material effect on the financial statements. We evaluated management's incentives and opportunities for fraudulent manipulation of the financial statements (including the risk of override of controls), and determined that the principal risks were related to posting inappropriate journal entries and management bias in accounting estimates. The group engagement team shared this risk assessment with the component auditors so that they could include appropriate audit procedures in response to such risks in their work. Audit procedures performed by the group engagement team and/or component auditors included:

- Understanding and evaluating the design and implementation of controls designed to prevent and detect irregularities and fraud
- Enquiries of management, those charged with governance and those responsible for legal and compliance matters, including the company's in-house legal function and internal audit, to identify actual and potential litigation and claims and any known or suspected instances of non-compliance with laws and regulations and fraud
- Reviewing minutes of meetings of those charged with governance
- Reviewing financial statement disclosures and testing to supporting documentation to assess compliance with applicable laws and regulations
- Incorporating elements of unpredictability into the audit procedures performed
- Challenging assumptions and judgements made by management in their significant accounting estimates and judgements, particularly in relation to the key audit matters above
- Identifying and testing journal entries based on our risk assessment, in particular any journal entries posted with unusual account combinations and evaluating the business rationale of significant transactions outside the normal course of business

There are inherent limitations in the audit procedures described above. We are less likely to become aware of instances of non-compliance with laws and regulations that are not closely related to events and transactions reflected in the financial statements. Also, the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery or intentional misrepresentations, or through collusion.

Our audit testing might include testing complete populations of certain transactions and balances, possibly using data auditing techniques. However, it typically involves selecting a limited number of items for testing, rather than testing complete populations. We will often seek to target particular items for testing based on their size or risk characteristics. In other cases, we will use audit sampling to enable us to draw a conclusion about the population from which the sample is selected.

A further description of our responsibilities for the audit of the financial statements is located on the FRC's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditors' report.

Use of this report

This report, including the opinions, has been prepared for and only for the company's members as a body in accordance with Chapter 3 of Part 16 of the Companies Act 2006 and for no other purpose. We do not, in giving these opinions, accept or assume responsibility for any other purpose or to any other person to whom this report is shown or into whose hands it may come save where expressly agreed by our prior consent in writing.

Other required reporting

Companies Act 2006 exception reporting

Under the Companies Act 2006 we are required to report to you if, in our opinion:

- we have not obtained all the information and explanations we require for our audit; or
- adequate accounting records have not been kept by the company, or returns adequate for our audit have not been received from branches not visited by us; or
- certain disclosures of directors' remuneration specified by law are not made; or
- the company financial statements and the part of the Directors' Remuneration Report to be audited are not in agreement with the accounting records and returns.

We have no exceptions to report arising from this responsibility.



Sam Taylor (Senior Statutory Auditor)
for and on behalf of PricewaterhouseCoopers LLP
Chartered Accountants and Statutory Auditors
Reading
19 March 2026


Kiniksa Pharmaceuticals International, plc**Company balance sheet
As at 31 December 2025
(In thousands)**

	Note	2024 \$	2025 \$
Fixed Assets			
Intangible assets	3	63	23
Investments	4	1,323,381	1,450,287
		1,323,444	1,450,310
Current Assets			
Debtors: amounts falling due within one year	5	27,425	43
Short-term investments	7	—	20,898
Cash at bank and in hand	8	289	17,189
		27,714	38,130
Current Liabilities			
Creditors: amounts falling due within one year	9	(18,261)	(4,855)
Net Current Assets		9,453	33,275
Total assets less current liabilities		1,332,897	1,483,585
Net Assets		1,332,897	1,483,585
Total equity			
Called up share capital	10	83	21
Share premium account	11	809,933	854,368
Share based payment reserve	11	16,125	41,673
Merger reserve	11	520,181	520,181
Profit and loss account	11	(13,425)	67,342
		1,332,897	1,483,585

The above Company balance sheet should be read in conjunction with the accompanying notes.

The Company has elected to take the exemption under Section 408 of the Companies Act from 2006 from presenting the Company statement of comprehensive income. The Parent Company net loss for the period 9 April 2024 through 31 December 2024 was \$13,425K and net income for the year ended 31 December 2025 was \$80,767K.

The financial statements were approved by the Board on 17 March 2026 and were signed on its behalf.

DocuSigned by:

 9EFBEB991C8E4E0...

Sanj K. Patel
 Chief Executive Officer and Chairman of the Board of Directors (principal executive officer)
 Date: 19 March 2026

The notes on pages 72 to 83 form part of these financial statements.

Kiniksa Pharmaceuticals International, plc

Company statement of changes in equity

For the year ended 31 December 2025

(In thousands)

	Called up share capital	Share premium account	Share based payment reserve	Merger relief reserve	Profit and loss account	Total equity
	\$	\$	\$	\$	\$	\$
At 9 April 2024	—	—	—	—	—	—
Share Issuance	63	—	—	—	—	63
Share issuance in consideration for the Consolidated Group	20	801,096	—	520,304	—	1,321,420
Issuance of ordinary shares under ESPP	—	488	—	—	—	488
Options exercised	—	11,631	—	—	—	11,631
Shares tendered for withholding taxes	—	(3,282)	—	—	—	(3,282)
Equity Awards	—	—	16,125	—	—	16,125
Impairment in Subsidiary	—	—	—	(123)	—	(123)
Net loss for the period	—	—	—	—	(13,425)	(13,425)
At 31 December 2024	83	809,933	16,125	520,181	(13,425)	1,332,897
Issuance of ordinary shares under ESPP	—	1,131	—	—	—	1,131
Options exercised	1	51,034	(11,422)	—	—	39,613
Shares tendered for withholding taxes	—	(7,730)	—	—	—	(7,730)
Share Redemption	(63)	—	—	—	—	(63)
Equity Awards	—	—	36,970	—	—	36,970
Net income for the year	—	—	—	—	80,767	80,767
At 31 December 2025	21	854,368	41,673	520,181	67,342	1,483,585

Kiniksa Pharmaceuticals International, plc
Notes to the financial statements
For the year ended 31 December 2025

General information

Kiniksa Pharmaceuticals International, plc (the “**Parent Company**”), and together with its subsidiaries, is a global biopharmaceutical company focused on discovering, acquiring, developing and commercialising therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need.

Kiniksa International is a public holding company incorporated in April 2024 under the laws of England and Wales with registration number 15630565. The Company’s UK headquarters and registered office address is 105 Piccadilly, Second Floor, London, England, W1J 7NJ. The Parent Company is quoted on the Nasdaq capital market under the ticker “KNSA.” The Parent Company and its direct and indirect subsidiaries, Kiniksa Pharmaceuticals Corp. (“**Kiniksa US**”), Kiniksa Pharmaceuticals, Ltd. (“**Kiniksa Bermuda**”), which was liquidated in November 2024, and Kiniksa Pharmaceuticals (UK), Ltd. (“**Kiniksa UK**”) as well as the subsidiaries of Kiniksa US, Primatope Therapeutics, Inc. (“**Primatope**”) and subsidiaries of Kiniksa UK, Kiniksa Pharmaceuticals (Germany) GmbH (“**Kiniksa Germany**”), Kiniksa Pharmaceuticals (France) SARL (“**Kiniksa France**”), and Kiniksa Pharmaceuticals, GmbH (“**Kiniksa Switzerland**”), are collectively referred to as the “Group”. The Group’s US headquarters are located at 100 Hayden Avenue, Lexington, MA 02421.

1. Accounting policies

1.1 Basis of preparation of Company financial statements

The financial statements have been prepared under the historical cost convention in accordance with The Financial Reporting Standard 102 (“**FRS 102**”), “The Financial Reporting Standard applicable in the UK and Republic of Ireland” and the Companies Act 2006.

The Group financial statements comprise both the Consolidated Financial Statements of Kiniksa Pharmaceuticals International, plc. on Form 10-K and the certain note disclosures relevant to the Group financial statements.

Accounting policies have been applied consistently other than when new policies have been adopted.

The Parent Company has taken advantage of the following disclosure exemptions in preparing these financial statements, as permitted by FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland”:

- the requirements of Section 7 Statement of Cash Flows and Section 3 Financial Statement Presentation paragraph 3.17(d);
- the requirements of Section 11 Financial Instruments paragraphs 11.42, 11.44, 11.45, 11.47, 11.48(a)(iii), 11.48(a)(iv), 11.48(b), 11.48(c), 12.26 (in relation to those cross-referenced paragraphs from which a disclosure exemption is available), 12.2, 12.29(a), 12.29(b), and 12.29A provided disclosures equivalent to those required by this FRS are included in the consolidated financial statements of the Group in which the entity is consolidated.
- the requirements of Section 26 Share-based Payments paragraphs 26.18(b), 26.19-26.21 and 26.23
- the requirements of Section 33 Related Party Disclosures paragraph 33.7;

Kiniksa Pharmaceuticals International, plc
Notes to the financial statements
For the year ended 31 December 2025

1.2 Going concern

The Parent Company generated a net income of \$80,767K for the year ended 31 December 2025 (net loss of \$13,425 K for the period 9 April 2024 through 31 December 2024). Management and the Directors have prepared budgets and forecasts, for at least the next 12 months from the date of approval of these consolidated financial statements, and expect the cash and cash equivalents on hand as of the date of signing will be sufficient to fund the Parent Company's operations and capital expenditure requirements for at least the next twelve months. As such the Directors are satisfied that the going concern basis is appropriate for the preparation of these financial statements.

1.3 Exemption from audit by parent guarantee

Under Section 479A of the Companies Act 2006, exemption from an audit of the financial statements for the financial year ending 31 December 2025 has been taken by Kiniksa Pharmaceuticals (UK), Ltd., registered number 1176038. As required, the Parent Company guarantees all outstanding liabilities to which Kiniksa UK is subject to at the end of the financial period, until they are satisfied in full and the guarantee is enforceable against the parent undertaking by any person to whom Kiniksa UK is liable in respect of those liabilities.

1.4 Foreign currency translation

Functional and presentation currency

The Parent Company's functional and presentational currency is USD.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions.

At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.

Foreign exchange gains and losses resulting from the settlement of transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in profit or loss.

Foreign exchange gains and losses that relate to cash and cash equivalents are presented in the Statement of comprehensive income within 'finance income or costs'. All other foreign exchange gains and losses are presented in profit or loss.

1.5 Share-based payments

The Parent Company measures all share-based awards granted to employees and directors based on their fair value on the date of grant. The Parent Company issues share-based awards with both service-based, performance-based and market-based vesting conditions. The Parent Company recognizes compensation expense for awards with service and market conditions

Kiniksa Pharmaceuticals International, plc
Notes to the financial statements
For the year ended 31 December 2025

on a straight-line basis over the requisite service period. For awards that contain performance conditions, the Parent Company determines the appropriate amount to expense based on the anticipated achievement of performance targets, which requires judgment, including forecasting the achievement of future specified targets. At the date performance conditions are determined to be probable of achievement, the Parent Company records a cumulative expense catch-up, with remaining expense amortized over the remaining service period. Throughout the performance period, the Parent Company re-assess the estimated performance and updates the number of performance-based awards that the Parent Company believes will ultimately vest.

For share-based awards granted to consultants and non-employees, compensation expense is recognized over the vesting period of the awards, which is generally the period during which services are rendered by such consultants and non-employees until completed.

The fair value of each option grant is estimated on the date of grant using the Black-Scholes option-pricing model, which requires inputs based on certain subjective assumptions, including the expected share price volatility, the expected term of the award, the risk-free interest rate for a period that approximates the expected term of the award and expected dividends. The fair value of each restricted share unit award is based on the closing price of the Parent Company's Class A ordinary shares on the date of grant, with the exception of PSUs with market conditions, which are measured using the Monte Carlo simulation method. The Monte-Carlo valuation model requires the use of assumptions, including but not limited to the expected volatility, correlation coefficients, risk free rate, expected dividend yield and expected term.

The financial effect of awards by the Parent Company of shares, share options, and restricted stock units over its equity shares to employees of subsidiary undertakings are recognised by the Parent Company in its individual financial statements. In the consolidated financial statements, the transaction is treated as an equity-settled share-based payment, as the Group has received services in consideration for the Group's equity instruments. An expense is recognised in the Group income statement for the amount calculated as outlined above over the vesting period, with a credit in equity.

In the subsidiaries' financial statements, the awards, in proportion to the recipients who are employees in said subsidiary, are treated as an equity-settled share-based payment, as the subsidiaries do not have an obligation to settle the award. An expense for the amount calculated as outlined above is recognised over the vesting period, with a credit recognised in equity. The credit to equity in their financial statements is treated as a capital contribution, as the Parent Company is compensating the subsidiaries' employees with no cost to the subsidiaries as there is no expectation to recharge this cost. In the Parent Company's financial statement's, there is no share-based payment charge where the recipients are employed by a subsidiary, with the Parent Company recognising an increase in the investment in the subsidiaries as a capital contribution from the parent and a credit to equity.

1.6 Share Capital

Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new ordinary shares or options are shown in equity as a deduction, net of tax, from the proceeds.

Kiniksa Pharmaceuticals International, plc
Notes to the financial statements
For the year ended 31 December 2025

1.7 Intangible assets

Intangible assets comprise computer software and are stated at capitalized cost less accumulated amortisation and accumulated impairment losses.

Amortisation is calculated, using the straight-line method, to allocate the depreciable amount of the assets to their residual values over their estimated useful lives, assessed by the directors on a case-by-case basis, as follows:

- Computer software: 5 years

The assets are reviewed for impairment if there is an indication that the carrying amount may be impaired. Provision is made against the carrying value of such assets when an impairment in value is deemed to have occurred.

Costs associated with maintaining computer software are recognised as an expense as incurred. Amortisation is included in other operating expenses in the statement of comprehensive income.

1.8 Valuation of investments

Investments are initially recorded at transaction price and subsequently measured at cost less accumulated impairment losses. The costs arising from group reorganization were based on the value of shares issued on the date of reorganization. Where at year end there is evidence of impairment, the carrying value of the investment is written down to its recoverable amount.

1.9 Debtors

Short-term debtors are measured at transaction price, less any impairment.

1.10 Short-term investments

Investments are classified as fair value through profit or loss (FVPL).

1.11 Cash

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours.

1.12 Creditors

Creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers.

Creditors are recognised at transaction price less attributable transaction costs.

1.13 Financial instruments

The Parent Company recognises financial instruments when it becomes a party to the contractual arrangements of the instrument. Financial instruments are de-recognised when they

Kiniksa Pharmaceuticals International, plc
Notes to the financial statements
For the year ended 31 December 2025

are discharged or when the contractual terms expire. The Parent Company's accounting policies in respect of financial instruments transactions are explained below:

Financial assets and financial liabilities are initially measured at fair value.

Financial assets

All recognised financial assets are subsequently measured in their entirety at either fair value or amortised cost, depending on the classification of the financial assets.

Fair value through profit or loss

All of the Parent Company's financial assets other than those which meet the criteria to be measured at amortised cost are subsequently measured at fair value at the end of each reporting period, with any fair value gains or losses being recognised in profit or loss to the extent they are not part of a designated hedging relationship. The net gain or loss recognised in profit or loss includes any dividend or interest earned on the financial asset.

Impairment of financial assets

The Parent Company recognises a loss allowance for expected credit losses on investments in debt instruments that are measured at amortised or at fair value through other comprehensive income ("FVOCI"). The amount of expected credit losses is updated at each reporting date to reflect changes in credit risk since initial recognition of the respective financial instrument.

The Parent Company always recognises lifetime expected credit losses ("ECL") for intercompany receivables and amounts due on contracts with customers. The expected credit losses on these financial assets are estimated based on the Parent Company's historical credit loss experience, adjusted for factors that are specific to the debtors, general economic conditions and an assessment of both the current as well as the forecast direction of conditions at the reporting date, including time value of money where appropriate. Lifetime ECL represents the expected credit losses that will result from all possible default events over the expected life of a financial instrument.

Financial liabilities

Fair value through profit or loss

Financial liabilities are classified as at fair value through profit or loss, when the financial liability is held for trading, or is designated as at fair value through profit or loss. This designation may be made if such designation eliminates or significantly reduces a measurement or recognition inconsistency that would otherwise arise, or the financial liability forms part of a group of financial instruments which is managed and its performance is evaluated on a fair value basis, or the financial liability forms part of a contract containing one or more embedded derivatives, and IFRS 9 permits the entire combined contract to be designated as at fair value through profit or loss. Any gains or losses arising on changes in fair value are recognised in profit or loss to the extent that they are not part of a designated hedging relationship.

Kiniksa Pharmaceuticals International, plc
Notes to the financial statements
For the year ended 31 December 2025

At amortised cost

Financial liabilities which are neither contingent consideration of an acquirer in a business combination, held for trading, nor designated as at fair value through profit or loss are subsequently measured at amortised cost using the effective interest method. This is a method of calculating the amortised cost of a financial liability and of allocating interest expense over the relevant period. The effective interest rate is the rate that exactly discounts estimated future cash payments through the expected life of the financial liability, or where appropriate a shorter period, to the amortised cost of a financial liability.

1.14 Dividends

Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders.

2. Critical accounting judgements

The preparation of the financial statements requires the directors to make judgments, estimates and assumptions that can affect the amounts reported for assets and liabilities, and the results for the year. The nature of estimation is such that actual outcomes could differ significantly from those estimates.

The following judgments have had the most significant impact on amounts recognised in the financial statements:

The Parent Company assesses at each reporting date whether an asset may be impaired or if amounts due from group undertakings require a provision. If any such indication exists, the Parent Company estimates the recoverable amount of the asset. The recoverable amount is the higher of its fair value less cost to sell and its value in use. If the recoverable amount is less than its carrying amount, the carrying amount of the asset is impaired and it is reduced to its recoverable amount through an impairment in profit and loss unless the asset is carried at a revalued amount where the impairment loss of a revalued asset is a revaluation decrease.

The valuation of the subsidiary is derived from publicly available information, being the market capitalisation of the Group, at the period end date, given that the future value of the Group is expected to be generated from the products and treatments which are being developed by the subsidiary companies. On the balance sheet date, where the market capitalisation of the Group as a whole falls below the carrying value of the investment, management will perform a fair value less cost to sell calculation and then consider whether an impairment of the investment is required, and if so, will write down the cost of the investment to its recoverable amount, with an associated impairment charge recognised in the Parent Company profit and loss account.

The Parent Company recorded an impairment of \$123K during the year ended 31 December 2024 associated with the contribution of Primatope to Kiniksa US. The Parent Company has assessed its remaining investments and amounts due from group undertakings for impairment indicators and did not identify any triggers; management have therefore determined there are no impairments to be recorded as of 31 December 2025.

Kiniksa Pharmaceuticals International, plc
Notes to the financial statements
For the year ended 31 December 2025

3. Intangible assets

	Computer Software (\$000)
Cost	
At 9 April 2024	—
Additions - external	80
At 31 December 2024	80
Disposals	(24)
At 31 December 2025	56
Accumulated amortisation of 31 December 2025 and 31 December 2024	
At 9 April 2024	—
Charge for the year	17
At 31 December 2024	17
Charge for the year	18
Disposals	(2)
At 31 December 2025	33
Net book value	
At 31 December 2024	63
At 31 December 2025	23

4. Investments

	Investments in subsidiary companies (\$000)
Cost	
At 9 April 2024	—
Additions	1,307,378
Shared-based payments associated with subsidiary employees	16,125
Measurement period adjustments	(122)
At 31 December 2024	1,323,381
Cost	
At 1 January 2025	1,323,381
Contributions	90,000
Shared-based payments associated with subsidiary employees	36,970
Share redemptions	(64)
At 31 December 2025	1,450,287

On 27 June 2024, the Parent Company and Kiniksa Bermuda completed a transaction pursuant to a Bermuda court-approved scheme of arrangement (the “Scheme”), which had been previously approved by Kiniksa Bermuda’s shareholders. Pursuant to the Scheme, the shareholders of Kiniksa Bermuda became the shareholders of the Parent Company and the Parent Company became the ultimate parent and holding company of the Kiniksa organization, thereby effecting a change of incorporation from Bermuda to the United Kingdom (the “Redomiciliation”). As part of the Scheme Kiniksa Bermuda transferred all of its right, title and interest in its assets and assigned and novated its liabilities to the Parent Company. As a result the Parent Company held direct investments in Kiniksa US, Kiniksa UK, Primatope and Kiniksa Bermuda following the Redomiciliation.

Kiniksa Pharmaceuticals International, plc
Notes to the financial statements
For the year ended 31 December 2025

In December 2024 the Parent Company contributed Primatope to Kiniksa US. The Parent Company remeasured the fair value of Primatope upon the contribution of Primatope from the Parent Company to Kiniksa US and recorded an impairment reflecting the change in fair value and an increase in the investment in Kiniksa US.

In 2025, the Parent Company contributed \$90,000K to Kiniksa Pharmaceuticals GmbH ("Kiniksa GmbH") a subsidiary of Kiniksa UK. In connection with this capital contribution, the Parent Company increased the book value of its investment in Kiniksa UK.

In 2025, 50,000 Preference shares of £1 each were redeemed by the Parent Company in order to remove Kiniksa Bermuda as a shareholder of the Parent Company as part of the Scheme. See footnote 10. Called up share capital for further details.

5. Debtors: amounts falling due within one year

	<u>2024</u>	<u>2025</u>
	(\$000)	(\$000)
Due within one year		
Amounts owed by group undertakings (1)	25,325	23
Prepayments and accrued income	2,100	20
At 31 December	<u>27,425</u>	<u>43</u>

(1) Amounts owed by group undertakings (1) are due within 60 days of quarter-end, relate to trading balances/recharges from the group, were unsecured and interest free.

6. Subsidiary undertakings

The following were subsidiary undertakings of the Parent Company:

Name	Country of incorporation	Registered address	Nature of business	Class of shares	Holdings
Kiniksa Pharmaceuticals Corp.	United States	100 Hayden Avenue, Lexington, MA, 02421	Operating	Ordinary	100%
Primatope Therapeutics, Inc.	United States	100 Hayden Avenue, Lexington, MA, 02421	Dormant	Ordinary	100% ¹
Kiniksa Pharmaceuticals (UK), Ltd.	United Kingdom	105 Piccadilly, Second Floor, London, W1J 7NJ, England, United Kingdom	Operating	Ordinary	100%
Kiniksa Pharmaceuticals (Germany) GmbH	Germany	Kronstadter Str. 4, Munich, Bayern 81677, Germany	Dormant	Ordinary	100% ²
Kiniksa Pharmaceuticals (France) SARL	France	12 place Dauphine 75001 Paris, France	Dormant	Ordinary	100% ²
Kiniksa Pharmaceuticals, GmbH	Switzerland	Grafenaustrasse 5, 6300 Zug, Switzerland	Operating	Ordinary	100% ²

(1) Held indirectly through Kiniksa Pharmaceuticals Corp.

Kiniksa Pharmaceuticals International, plc
Notes to the financial statements
For the year ended 31 December 2025

(2) Held indirectly through Kiniksa Pharmaceuticals (UK), Ltd.

In November 2025, Kiniksa Bermuda was liquidated as part of the completion of the Scheme. See footnote 10. Called up share capital for further details.

7. Short-term Investments

	<u>2024</u> <u>(\$000)</u>	<u>2025</u> <u>(\$000)</u>
Current Investments		
Fixed income securities at fair value through profit or loss	—	20,898
Total	—	20,898

The fair value of listed investments is based on year end quoted market prices.

Fair value hierarchy

The table below analyses equity securities and bonds, contained within Short-term investments and carried at fair value, by valuation method.

The different levels have been defined as follows:

- Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities
- Level 2: inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices)
- Level 3: inputs for the asset or liability that are not based on observable market data (unobservable inputs).

	<u>2024</u> <u>FVPL</u> <u>(\$000)</u>	<u>2025</u> <u>FVPL</u> <u>(\$000)</u>
Level 2	—	20,898
Total	—	20,898

During the period ended 31 December 2024 and the year ended 31 December 2025 there were no transfers between Level 1, Level 2 and Level 3.

8. Cash at bank and in hand

	<u>2024</u> <u>(\$000)</u>	<u>2025</u> <u>(\$000)</u>
Cash at bank in hand	289	17,189

Kiniksa Pharmaceuticals International, plc
Notes to the financial statements
For the year ended 31 December 2025

9. Creditors: Amounts falling due within one year

	<u>2024</u>	<u>2025</u>
	(\$000)	(\$000)
Trade creditors	20	—
Amounts owed to group undertakings (1)	15,774	3,142
Corporation tax	1,561	1,683
Accruals and deferred income	906	30
At 31 December	<u>18,261</u>	<u>4,855</u>

(1) Amounts owed to group undertakings are unsecured, interest free and payable no later than 75 days after quarter end.

10. Called up share capital

The Parent Company was in April 2024 incorporated with 1 Ordinary share of £0.01 (the “KNSA Bermuda Ordinary Share”) and 50,000 Preference shares of £1 each (the “KNSA Bermuda Preference Shares”) (total allotted share capital of £50,000.01). All shares were allotted to Kiniksa Bermuda in 27 June 2024, the Parent Company and Kiniksa Bermuda completed a transaction pursuant to a Bermuda court-approved Scheme, which had been previously approved by Kiniksa Bermuda’s shareholders. Pursuant to the Scheme, the shareholders of Kiniksa Bermuda became the shareholders of the Parent Company and the Parent Company became the ultimate parent and holding company of the Kiniksa organization, thereby effecting a change of incorporation from Bermuda to the United Kingdom.

In the year ending 31 December 2025, the 1 KNSA Bermuda Ordinary Share was gifted to the Parent Company for nil consideration; and the 50,000 KNSA Bermuda Preference Shares were redeemed in order to remove Kiniksa Bermuda as a shareholder of the Parent Company. In November 2025, Kiniksa Bermuda was liquidated as part of the completion of the Scheme. As of 31 December 2025 there are no KNSA Bermuda Ordinary Share or KNSA Bermuda Preference Shares outstanding. In November 2025, Kiniksa Bermuda was liquidated as part of the completion of the Scheme.

As of 31 December 2025, the Parent Company had four classes of ordinary shares outstanding: Class A, Class B, Class A1 and Class B1. For a full description of the Parent Company’s share capital, including the rights attaching thereto, see Exhibit 4.3 to the Form 10-K.

Kiniksa Pharmaceuticals International, plc
Notes to the financial statements
For the year ended 31 December 2025

	<u>2024</u> <u>(\$000)</u>	<u>2025</u> <u>(\$000)</u>
Allotted, called up and fully paid		
Ordinary Shares, £0.01 per share, nil shares and 1 share of as of 31 December 2025 and 2024, respectively	—	—
Preference shares, £1 each per share, nil shares and 50,000 shares of 31 December 2025 and 2024, respectively	63	—
Class A ordinary shares, \$0.000273235 per share; 45,659,424 shares and 41,881,319 shares as of 31 December 2025 and 2024, respectively	11	12
Class B ordinary shares, \$0.000273235 per share; 1,795,158 shares as of 31 December 2025 and 2024	1	1
Class A1 ordinary shares, \$0.000273235 par value; 12,781,964 shares as of 31 December 2025 and 2024	4	4
Class B1 ordinary shares, \$0.000273235 par value; 16,057,618 shares as of 31 December 2025 and 2024	4	4
At 31 December	<u>83</u>	<u>21</u>

11. Reserves

Share premium account

This reserve represents the excess of the fair value of the consideration receivable on the issue of ordinary share capital, net of the direct costs incurred in their issue, over the nominal value of those shares (which is recognised as called up share capital), by way of a share for share exchange.

Share based payment reserve

This reserve represents the value of share-based payments granted by the Parent Company.

Merger reserve

This reserves represents the premium that was created from the redomiciliation transaction by the Parent Company in June 2024. Ordinary shares in the Parent Company were issued to acquire the entire issued share capital of Kiniksa Bermuda. Under section 612 of the UK Companies Act 2006, the premium on these shares has been included in a merger relief reserve.

Profit and loss account

This reserve comprises all current and prior period retained profits and losses after deducting any distributions made to the Parent Company's shareholders.

12. Related party transactions

The Parent Company has taken the exemption available under FRS 102 regarding related party transactions entered into between two or more members of a group, provided that the subsidiaries party to the transaction are wholly owned by a member of the group.

13. Post balance sheet events

Disclosed as part of the Note 19 in the Notes to the Consolidated Financial Statements.

Kiniksa Pharmaceuticals International, plc
Notes to the financial statements
For the year ended 31 December 2025

14. Controlling party

There is no ultimate parent undertaking or controlling party of the Parent Company as ownership is split between the Parent Company's shareholders.

Certain Note Disclosures Relevant to the Group Financial Statements

Basis of Preparation

Kiniksa Pharmaceuticals International, plc is a public limited company, incorporated in April 2024, and is the successor entity to Kiniksa Pharmaceuticals, Ltd. See “Strategic Report – Introduction”, for more information. The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) as permitted under statutory instrument 1675, “The Accounting Standards (Prescribed Bodies) (United States of America and Japan) (Amendment) Regulations 2015” and now amended by “The Accounting Standards (Prescribed Bodies) (United States of America and Japan) (Amendment) Regulations 2023 (SI 2023/975)” and in accordance with the UK Companies Act 2006. The Group financial statements comprise both the Consolidated Financial Statements of Kiniksa Pharmaceuticals International, plc on Form 10-K and the Certain Note Disclosures Relevant to the Group Financial Statements. There are 2 years remaining for which Kiniksa Pharmaceuticals International, plc may prepare accounts under the 2023 Regulations.

The initial set of Consolidated Financial Statements have been prepared as if the Group had been in existence throughout all the periods presented by applying the principles of predecessor accounting in accordance with SEC Regulation C Rule 405 and IFRS although the actual legal transaction and corporate reorganisation occurred in June 2024. There was no economic change or event impacting the reporting entity because the business activities of the predecessor and successor remained identical and only the legal form and ownership allocation has changed.

The company financial statements have been prepared in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards, comprising FRS 102 “The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland” and applicable law) and UK Companies Act 2006.

Statutory Disclosure Requirements

Monthly average number of people employed:

	<u>Year ended 31 December</u>	
	<u>2024</u>	<u>2025</u>
UK		
<i>General and Administrative</i>	1	1
<i>Commercial</i>	6	7
Total UK Employees	7	8
Offshore⁽¹⁾		
<i>General and Administrative</i>	86	92
<i>Commercial</i>	121	151
<i>Research & Development</i>	95	87
Total Offshore Employees	<u>302</u>	<u>330</u>
Total Employees	309	338

(1) Offshore employees include employees employed in the United States and Switzerland.

(i) Employee costs:

Group	Year ended 31 December	
	2024	2025
Salaries and bonuses	\$ 85,173,898	\$ 99,629,188
Share-based compensation expense	\$ 30,692,761	\$ 37,004,312
Benefits⁽¹⁾	\$ 8,548,959	\$ 9,915,295
Social insurance and social security costs	\$ 5,506,504	\$ 7,116,608
Total Employee Costs	\$ 129,922,122	\$ 153,665,403

(1) Amount shown represents health insurance, life insurance, disability insurance and 401(k) matching contributions.

Auditor remuneration

During the year, the Group obtained the following services from the Company's auditors.

Group	Year ended 31 December	
	2024	2025
<i>Fees payable to the Company's auditors for the audit of Kiniksa Pharmaceuticals International, plc and its subsidiaries and consolidated financial statements</i>	\$ 2,076,600	\$ 1,987,560
<i>Audit-related assurance services</i>	—	—
<i>Other assurance services</i>	\$ 2,000	\$ 5,060
Total auditor remuneration	\$ 2,078,600	\$ 1,992,620

A resolution to reappoint the firm as auditors will be put to shareholders for ratification at the 2026 AGM on 29 May 2026.